WO2016151295A1 - Fluorination process - Google Patents

Fluorination process Download PDF

Info

Publication number
WO2016151295A1
WO2016151295A1 PCT/GB2016/050758 GB2016050758W WO2016151295A1 WO 2016151295 A1 WO2016151295 A1 WO 2016151295A1 GB 2016050758 W GB2016050758 W GB 2016050758W WO 2016151295 A1 WO2016151295 A1 WO 2016151295A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
silver
compound
group
Prior art date
Application number
PCT/GB2016/050758
Other languages
French (fr)
Inventor
Veronique Gouverneur
Matthew TREDWELL
Original Assignee
Oxford University Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Limited filed Critical Oxford University Innovation Limited
Publication of WO2016151295A1 publication Critical patent/WO2016151295A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C07C17/14—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/20—Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
    • C07C17/202—Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms two or more compounds being involved in the reaction
    • C07C17/208—Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms two or more compounds being involved in the reaction the other compound being MX
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/361—Preparation of halogenated hydrocarbons by reactions involving a decrease in the number of carbon atoms
    • C07C17/363—Preparation of halogenated hydrocarbons by reactions involving a decrease in the number of carbon atoms by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
    • C07C323/09—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to a process for producing an organic compound comprising an 18 F atom.
  • the present invention also relates to the use of activators in the [ 18 F]radiolabelling of organic compounds, kits comprising activators, compositions comprising radiolabelled compounds and [ 18 F]radiolabelled compounds.
  • PET Positron Emission Tomography
  • radioisotope due to its advantageous properties (a radioactive half-life of 109.771 minutes allowing for imaging durations of up to 10 hours, 97% positron emission, positron energy), the extensive use of 2-deoxy-2-[ 18 F]fluoroglucose ([ 18 F]FDG) in the clinic, and the importance of fluorine substitution in the context of drug discovery.
  • the success of PET and the increasing interest in [ 18 F]radiochemistry recently led to creative methods to incorporate 18 F into molecules of increasing complexity.
  • clinically useful radiotracers lie within a narrow accessible space, with [ 18 F]fluoroalkanes and
  • [ 18 F]fluoroarenes at the forefront. Many potentially high value PET [ 18 F]labelled tracers and drugs lie outside this radiochemical space, and the ability to test tracers not amenable to traditional [ 18 F]labelling intervention would be a major boost for PET imaging. Medicinal chemists would immediately benefit from a more diverse range of 18 F-tags to perform in vivo studies that could inform the selection of leads for further optimization earlier in the drug discovery pipeline. Drug developers employ routinely di- and trifluoromethyl ether and thioether substitution to tune conformation on demand, or modulate physicochemical parameters such as lipophilicity.
  • riluzole an OCF 3 containing 2-amino benzothiazole and the first drug approved for the treatment of amyotropic lateral sclerosis
  • tiflorex an SCF3 substituted 2-phenylethylamine which possesses anorectic activity.
  • Radiochemists have employed halogen exchange [ 18 F]fluorination for many years; alkyl halides and halogenated arenes activated by an electron withdrawing group (e.g. N0 2 ) respond to halex [ 18 F]fluorination.
  • an electron withdrawing group e.g. N0 2
  • the method was applied to convert 2- and 4- chloropyridines to [ 18 F]fluorinated analogues but has met with limited success for RCF 2 X precursors since the presence of two a-fluorines severely inhibits nucleophilic substitution. Harsh reaction conditions permit access to [ 18 F]aryl-CF 3 , but the low radiochemical yields and specific activities implied that this chemistry has prohibitively narrow applicability. It is therefore greatly desirable to develop a new method for applying halogen exchange
  • [ 18 F]radiolabelled compounds comprising a -CF 2 18 F or related group can be produced under very mild conditions. This enables the production of [ 18 F]radiolabelled samples with high specific activities.
  • the invention therefore provides a process for producing an organic compound comprising an 18 F atom, which process comprises treating a precursor organic compound comprising a -CY 2 X group with:
  • an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein:
  • X is a leaving group; and each Y is independently selected from F, CI, Br and H.
  • the invention also provides the use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom as defined herein.
  • kit for [ 18 F]radiolabelling an organic compound which kit comprises:
  • an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum; and (ii) a precursor organic compound comprising a -CY 2 X group, wherein X is a leaving group and each Y is independently selected from F, CI, Br and H.
  • the invention also provides a composition comprising a compound of formula:
  • R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; and R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • the invention also provides a compound which is [ 18 F]sorafenib, [ 18 F]aprepitant,
  • organic group refers to a group derived by removing a hydrogen atom from an organic compound.
  • An organic compound is typically a compound comprising a hydrogen atom bonded to a carbon atom, but may also include compounds comprising a covalent bond between carbon and another atom.
  • the term organic compound is well known in the art.
  • C1-60 organic group refers to an organic group comprising from 1 to 60 carbon atoms.
  • Ci-40 organic group refers to an organic group comprising from 1 to 40 carbon atoms.
  • an example of a C10 organic group is a group derived by removing a hydrogen atom from an organic compound which contains 10 carbon atoms.
  • a C1-60 organic group is a substituted or unsubstituted aryl group or a substituted or unsubstituted hetroaryl group.
  • alkyl group refers to a straight or branched chain saturated hydrocarbon radical.
  • an alkyl group is C 1-20 alkyl, or C 1-10 alkyl, for example methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl (including straight or branched chain isomers thereof), or Ci-6 alkyl, for example methyl, ethyl, propyl, butyl, pentyl or hexyl (including straight or branched chain isomers thereof), or C1-4 alkyl, for example methyl, ethyl, i-propyl, n-propyl, t-butyl, s-butyl or n-butyl.
  • an alkyl group When an alkyl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or
  • alkyl groups include haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl and alkaryl groups.
  • alkaryl as used herein, pertains to a C 1-20 alkyl group in which at least one hydrogen atom has been replaced with an aryl group.
  • Examples of such groups include, but are not limited to, benzyl (phenylmethyl, PI1CH2-), benzhydryl (Ph 2 CH-), trityl (triphenylmethyl, Ph 3 C-), and phenethyl (phenyl ethyl, Ph-CH 2 CH 2 -).
  • a substituted alkyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
  • perfluoroalkyl refers to a group which is a straight or branched chain saturated perfluonnated hydrocarbon radical.
  • a perfluoroalkyl group may be have from a to 12 carbon atoms.
  • Perfluonnated in this context means completely fluorinated such that there are no carbon-bonded hydrogen atoms replaceable with fluorine.
  • C 4-12 perfluoro alkyl groups are trifluoromethyl (Ci), pentafluoroethyl (C 2 ), hetptafluoropropyl (C 3 ), perfluorobutyl (C 4 ) (for instance including perfluoro- «-butyl, perfluoro-sec-butyl and perfluoro-tert-butyl), perfluoropentyl (C 5 ), perfluorohexyl (C 6 ), perfluoroheptyl (C 7 ), perfluorooctyl (C 8 ), perfluorononyl (Cs>), perfluorodecyl (Cio), perfluoroundecyl (Cn) and perfluorododecyl (C 12 ), including straight chained and branched isomers thereof.
  • alkenyl refers to a linear or branched chain hydrocarbon radical comprising one or more double bonds.
  • An alkenyl group may be a C 2-2 o alkenyl group, a C 2- io alkenyl group or a C 2- 6 alkenyl group.
  • Examples of C 2-2 o alkenyl groups include those related to C 2-2 o alkyl groups by the insertion of one or more double bonds.
  • Alkenyl groups typically comprise one or two double bonds.
  • the alkenyl groups referred to herein may be substituted or unsubstituted, as defined for alkyl groups above.
  • alkynyl refers to a linear or branched chain hydrocarbon radical comprising one or more triple bonds.
  • An alkynyl group may be a C 2-2 o alkynyl group, a C 2-10 alkynyl group a C 2- 6 alkynyl group.
  • Examples of C 2-2 o alkynyl groups include those related to C 2-2 o alkyl groups by the insertion of one or more triple bonds.
  • Alkynyl groups typically comprise one or two triple bonds.
  • the alkynyl groups referred to herein may be substituted or unsubstituted, as defined for alkyl groups above.
  • cycloalkyl group refers to an substituted or unsubstituted alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound.
  • a cycloalkyl group may have from 3 to 25 carbon atoms (unless otherwise specified), including from 3 to 25 ring atoms.
  • cycloalkyl includes the sub-classes cycloalkyenyl and cycloalkynyl.
  • Examples of groups of C 3-25 cycloalkyl groups include C 3-2 o cycloalkyl, C 3-15 cycloalkyl, C 3-10 cycloalkyl, and C 3 - 7 cycloalkyl.
  • a C 3-25 cycloalkyl group When a C 3-25 cycloalkyl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid,
  • a substituted cycloalkyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
  • C3-25 cycloalkyl groups include, but are not limited to, those derived from saturated monocyclic hydrocarbon compounds, which C3-25 cycloalkyl groups are substituted or unsubstituted as defined above: cyclopropane (C 3 ), cyclobutane (C 4 ), cyclopentane (C5), cyclohexane (C 6 ), cycloheptane (C 7 ), methylcyclopropane (C 4 ), dimethylcyclopropane (C5), methylcyclobutane (C5), dimethylcyclobutane (C 6 ), methylcyclopentane (C 6 ),
  • dimethylcyclopentene C 7
  • methylcyclohexene C 7
  • dimethylcyclohexene C 8
  • saturated polycyclic hydrocarbon compounds thujane (Cio), carane (Cio), pinane (Cio), bornane (Cio), norcarane (C 7 ), no inane (C 7 ), norbornane (C 7 ), adamantane (Cio), decalin
  • heterocyclyl group refers to an substituted or unsubstituted monovalent moiety obtained by removing a hydrogen atom from a ring atom of a
  • heterocyclic compound which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms.
  • Heterocyclic compounds include aromatic heterocyclic compounds and non-aromatic heterocyclic compounds.
  • each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
  • a C3- 20 heterocyclyl group When a C3- 20 heterocyclyl group is substituted it typically bears one or more substituents selected from Ci-6 alkyl which is unsubstituted, aryl (as defined herein), cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, aiylamino, diaiylamino, aiylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e.
  • thiol -SH
  • a substituted C 3-20 heterocyclyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
  • groups of heterocyclyl groups include C 3-20 heterocyclyl, C5-20 heterocyclyl, C3-15 heterocyclyl, C5-15 heterocyclyl, C3 -12 heterocyclyl, C5-12 heterocyclyl, C3 -10 heterocyclyl, C5-10 heterocyclyl, C3-7 heterocyclyl, C5-7 heterocyclyl, and C5-6 heterocyclyl.
  • Examples of (non-aromatic) monocyclic C 3-20 heterocyclyl groups include, but are not limited to, those derived from:
  • Ni aziridine (C3), azetidine (C4), pyrrolidine (tetrahydropyrrole) (C5), pyrroline (e.g.,
  • Oi oxirane (C3), oxetane (C4), oxolane (tetrahydrofuran) (C5), oxole (dihydrofuran) (C5), oxane (tetrahydropyran) (C 6 ), dihydropyran (C 6 ), pyran (C 6 ), oxepin (C7);
  • O2 dioxolane (C5), dioxane (C 6 ), and dioxepane (C7);
  • N2 imidazolidine (C5), pyrazolidine (diazolidine) (C5), imidazoline (C5), pyrazoline
  • N1O1 tetrahydrooxazole (C5), dihydrooxazole (C5), tetrahydroisoxazole (C5),
  • dihydroisoxazole C5
  • morpholine C 6
  • tetrahydrooxazine C 6
  • dihydrooxazine C 6
  • oxazine C 6
  • N1S1 thiazoline (C5), thiazolidine (C5), thiomorpholine (C 6 );
  • O1S1 oxathiole (C5) and oxathiane (thioxane) (C 6 ); and,
  • N1O1S1 oxathiazine (C 6 ).
  • substituted (non-aromatic) monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C5), such as
  • arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse and pyranoses (C 6 ), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
  • heteroaryl groups examples include C 3-20 heterocyclyl groups which are also aryl groups are described below as heteroaryl groups.
  • aryl group refers to a substituted or unsubstituted, monocyclic or poly cyclic (for instance bicyclic) aromatic group which typically contains from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms in the ring portion. Examples include phenyl, naphthyl, indenyl, indanyl, anthracenyl and pyrenyl groups. An aryl group is substituted or unsubstituted.
  • an aryl group When an aryl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e.
  • a substituted aryl group may be substituted in two positions with a single Ci-6 alkylene group, or with a bidentate group represented by the formula -X-Ci-6 alkylene, or -X-Ci-6 alkylene-X-, wherein X is selected from O, S and R, and wherein R is H, aryl or C 1-6 alkyl.
  • a substituted aryl group may be an aryl group fused with a cycloalkyl group or with a heterocyclyl group.
  • aralkyl as used herein, pertains to an aryl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been substituted with a Ci-6 alkyl group.
  • groups include, but are not limited to, tolyl (from toluene), xylyl (from xylene), mesityl (from mesitylene), and cumenyl (or cumyl, from cumene), and duryl (from durene).
  • heteroaryl group refers to a substituted or unsubstituted, monocyclic or polycyclic (for instance bicyclic) aromatic group which typically contains from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms in the ring portion wherein the ring atoms of the group include one or more heteroatoms.
  • a heteroaryl group is a substituted or unsubstituted monocyclic or polycyclic (for instance bicyclic) heteroaromatic group which typically contains from 6 to 14 atoms, for instance 6 to 10 atoms, in the ring portion including one or more heteroatoms.
  • heteroaryl group includes pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolyl and isoquinolyl.
  • a heteroaryl group may be substituted or unsubstituted, for instance, as specified above for aryl. Typically it carries 0, 1, 2 or 3 substituents.
  • alkylene group refers to an substituted or unsubstituted bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated.
  • alkylene includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.
  • Ci-6 alkylene typically it is C 1-10 alkylene, for instance Ci-6 alkylene.
  • Ci-4 alkylene for example methylene, ethylene, i-propylene, n-propylene, t-butylene, s-butylene or n-butylene. It may also be pentylene, hexylene, heptylene, octylene and the various branched chain isomers thereof.
  • An alkylene group may be substituted or unsubstituted, for instance, as specified above for alkyl. Typically a substituted alkylene group carries 1, 2 or 3
  • the prefixes e.g., Ci-4, C 1-7 , C 1-20 , C 2-7 , C 3-7 , etc.
  • the term "Ci-4alkylene,” as used herein, pertains to an alkylene group having from 1 to 4 carbon atoms.
  • groups of alkylene groups include Ci-4 alkylene ("lower alkylene”), C 1-7 alkylene, C 1-10 alkylene and C 1-20 alkylene.
  • linear saturated C 1-7 alkylene groups include, but are not limited to, -(03 ⁇ 4) ⁇ - where n is an integer from 1 to 7, for example, -CH 2 - (methylene), -CH2CH2- (ethylene), -CH2CH2CH2- (propylene), and -CH2CH2CH2CH2- (butylene).
  • branched saturated C 1-7 alkylene groups include, but are not limited
  • Partially unsaturated alkylene groups comprising one or more double bonds may be referred to as alkenylene groups.
  • Partially unsaturated alkylene groups comprising one or more triple bonds may be referred to as alkynylene groups (for instance - C ⁇ C-, CH 2 -C ⁇ C-, and -CH 2 -C ⁇ C-CH 2 -).
  • alkynylene groups for instance - C ⁇ C-, CH 2 -C ⁇ C-, and -CH 2 -C ⁇ C-CH 2 -.
  • Examples of alicyclic saturated C 1-7 alkylene groups include, but are not limited to, cyclopentylene (e.g., cyclopent-l,3-ylene), and cyclohexylene (e.g., cyclohex-l,4-ylene).
  • alicyclic partially unsaturated C 1-7 alkylene groups include, but are not limited to, cyclopentenylene (e.g., 4-cyclopenten-
  • cyclohexenylene e.g., 2-cyclohexen-l,4-ylene; 3-cyclohexen-l,2-ylene; 2,5-cyclohexadien- 1,4-ylene.
  • C 1-20 alkylene and C 1-20 alkyl groups as defined herein are either uninterrupted or interrupted by one or more heteroatoms or heterogroups, such as S, O or N(R") wherein R" is H, Ci-6 alkyl or aryl (typically phenyl), or by one or more arylene (typically phenylene) groups, or by one or more -C(O)- or -C(0)N(R")- groups.
  • the phrase "optionally interrupted” as used herein thus refers to a C 1-20 alkyl group or an alkylene group, as defined above, which is uninterrupted or which is interrupted between adjacent carbon atoms by a heteroatom such as oxygen or sulfur, by a heterogroup such as N(R") wherein R" is H, aryl or Ci-C 6 alkyl, or by an arylene group, or by a -C(O)- or -C(0)N(R")- group, again wherein R" is H, aryl or Ci-C 6 alkyl.
  • a C 1-20 alkyl group such as n-butyl may be interrupted by the heterogroup N(R") as follows: -CH 2 N(R")CH 2 CH 2 CH 3, -CH 2 CH 2 N(R")CH 2 CH 3 , or -CH 2 CH 2 CH 2 N(R")CH 3 .
  • an alkylene group such as n-butylene may be interrupted by the heterogroup N(R") as follows: -CH 2 N(R")CH 2 CH 2 CH 2 - , -CH 2 CH 2 N(R")CH 2 CH 2 -, or -CH 2 CH 2 CH 2 N(R")CH 2 -.
  • an interrupted group for instance an interrupted C 1-20 alkylene or C 1-20 alkyl group, is interrupted by 1, 2 or 3 heteroatoms or heterogroups or by 1, 2 or 3 arylene (typically phenylene) groups. More typically, an interrupted group, for instance an interrupted C 1-20 alkylene or C 1-20 alkyl group, is interrupted by 1 or 2 heteroatoms or heterogroups or by 1 or 2 arylene (typically phenylene) groups.
  • a C 1-20 alkyl group such as n-butyl may be interrupted by 2 heterogroups N(R") as follows: -CH 2 N(R")CH 2 N(R")CH 2 CH 3 .
  • An arylene group is an substituted or unsubstituted bidentate moiety obtained by removing two hydrogen atoms, one from each of two different aromatic ring atoms of an aromatic compound, which moiety has from 5 to 14 ring atoms (unless otherwise specified).
  • each ring has from 5 to 7 or from 5 to 6 ring atoms.
  • An arylene group may be substituted or unsubstituted, for instance, as specified above for aryl.
  • the prefixes e.g., C5-20, C 6 -2o, C5-14, C5-7, C5-6, etc.
  • the term "C5-6 arylene,” as used herein, pertains to an arylene group having 5 or 6 ring atoms.
  • groups of arylene groups include C5-20 arylene, C 6 -2o arylene, C5-14 arylene, C 6 -i4 arylene, C 6 -io arylene, C5-12 arylene, C5-10 arylene, C5-7 arylene, C5-6 arylene, C5 arylene, and C 6 arylene.
  • the ring atoms may be all carbon atoms, as in "carboarylene groups” (e.g., C6-20
  • carboarylene C 6 -i4 carboarylene or C 6 -io carboarylene).
  • C 6 -2o arylene groups which do not have ring heteroatoms include, but are not limited to, those derived from the compounds discussed above in regard to aryl groups, e.g. phenylene, and also include those derived from aryl groups which are bonded together, e.g. phenyl ene-phenylene (diphenylene) and phenylene-phenylene- phenylene (triphenylene).
  • the ring atoms may include one or more heteroatoms, as in " heteroaryl ene groups” (e.g., Cs-io heteroarylene).
  • C5-10 heteroarylene groups include, but are not limited to, those derived from the compounds discussed above in regard to heteroaryl groups.
  • R is an acyl substituent, for example, a substituted or unsubstituted C 1-20 alkyl group, substituted or unsubstituted C 2-20 alkenyl group, substituted or unsubstituted C 2-20 alkynyl group, a substituted or unsubstituted C 3-20 heterocyclyl group, a substitute
  • acyloxy (or reverse ester) represents a group of
  • R is an acyloxy substituent, for example, a substituted or unsubstituted C 1-20 alkyl group, substituted or unsubstituted C 2-20 alkenyl group, substituted or unsubstituted C 2 -2o alkynyl group, a substituted or unsubstituted C3 -20 heterocyclyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, for instance a substituted or unsubstituted Ci-6 alkyl group.
  • ester groups include, but are not limited
  • amino represents a group of formula - H2.
  • C1-C10 alkylamino represents a group of formula - HR ' wherein R ' is a C 1-10 alkyl group, preferably a Ci-6 alkyl group, as defined previously.
  • di(C 1-10 )alkylamino represents a group of formula - R ' R ' ' wherein R ' and R ' ' are the same or different and represent C 1-10 alkyl groups, preferably Ci-6 alkyl groups, as defined previously.
  • arylamino represents a group of formula -NHR ' wherein R ' is an aryl group, preferably a phenyl group, as defined previously.
  • diarylamino represents a group of formula -NR ' R ' ' wherein R ' and R ' ' are the same or different and represent aryl groups, preferably phenyl groups, as defined previously.
  • arylalkylamino represents a group of formula -NR ' R " wherein R ' is a C 1-10 alkyl group, preferably a Ci-6 alkyl group, and R " is an aryl group, preferably a phenyl group.
  • a halo group is chlorine, fluorine, bromine or iodine (a chloro group, a fluoro group, a bromo group or an iodo group). It is typically chlorine, fluorine or bromine.
  • R and R together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.
  • acylamide groups include, but are not limited
  • a substituted Ci -2 o alkyl group may comprise an acylamido substituent defined by the formula
  • R 1 and R 2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:
  • a C 1-10 alkylthio group is a said C 1-10 alkyl group, preferably a Ci-6 alkyl group, attached to a thio group.
  • An arylthio group is an aryl group, preferably a phenyl group, attached to a thio group.
  • a C 1-20 alkoxy group is a said substituted or unsubstituted Ci -2 o alkyl group attached to an oxygen atom.
  • a Ci-6 alkoxy group is a said substituted or unsubstituted Ci-6 alkyl group attached to an oxygen atom.
  • a C1-4 alkoxy group is a substituted or unsubstituted C1-4 alkyl group attached to an oxygen atom.
  • Said Ci -2 o, Ci-6 and C1-4 alkyl groups are optionally interrupted as defined herein. Examples of C1-4 alkoxy groups include, -OMe
  • Ci- 2 o alkoxy groups are -O(Adamantyl), -0-CH 2 -Adamantyl and -0-CH 2 -CH 2 -Adamantyl.
  • An aryloxy group is a substituted or unsubstituted aryl group, as defined herein, attached to an oxygen atom.
  • An example of an aryloxy group is -OPh (phenoxy).
  • a reference to carboxylic acid or carboxyl group also includes the anionic (carboxylate) form (-COO " ), a salt or solvate thereof, as well as conventional protected forms.
  • a reference to an amino group includes the protonated form (- ⁇ HR ⁇ 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
  • a reference to a hydroxyl group also includes the anionic form (-0 " ), a salt or solvate thereof, as well as conventional protected forms.
  • Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and 1-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair- forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or
  • isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
  • a reference to a methoxy group, -OCH3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH2OH.
  • a reference to ortho- chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
  • Ci-7alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
  • keto/enol illustrated below
  • imine/enamine amide/imino alcohol
  • amidine/amidine amidine/amidine
  • nitroso/oxime
  • H may be in any isotopic form, including 3 ⁇ 4, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 0 and 18 0; and the like, unless otherwise specified.
  • reference to an isotope of fluorine refers only to that isotope of fluorine.
  • reference to 18 F includes only 18 F.
  • Reference to fluorine without specifying the isotope may refer to 18 F or 19 F depending on context.
  • reference to "F" i.e.
  • a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
  • Methods for the preparation e.g., asymmetric synthesis
  • separation e.g., fractional crystallisation and chromatographic means
  • isomeric forms are either known in the art or are readily obtained by adapting known methods, in a known manner.
  • substituted as used herein, may be as defined above for particular groups, e.g. for alkyl.
  • substituted typically refers to a group substituted with a group selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, formyl, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e.
  • substituted may refer to a group substituted with a group selected from substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, Ci-6 alkylamino, di(Ci-6)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, Ci-6 alkoxy, aryloxy, haloal
  • substituted may refer to a group substituted with a group selected unsubstituted Ci-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl, unsubstituted aryl, unsubstituted heteroaryl, cyano, amino, unsubstituted Ci-6 alkylamino, unsubstituted di(Ci-6)alkylamino, unsubstituted arylamino, unsubstituted diarylamino, unsubstituted arylalkylamino, unsubstituted amido, unsubstituted acylamido, hydroxy, oxo, halo, carboxy, unsubstituted ester, unsubstituted acyl, unsubstituted acyloxy, unsubstituted Ci-6 alkoxy, unsubstituted aryloxy, sulf
  • 18 F refers to an atom of the specific isotope of fluorine having 9 protons and 9 neutrons.
  • 18 F ⁇ refers to an anion of the atom of the specific isotope of fluorine having 9 protons and 9 neutrons.
  • protecting group takes its normal meaning in the art.
  • a protecting group is a group which is introduced into a compound so that a subsequent step is chemo selective and does not affect the protected group.
  • Protecting groups may be categorised as those suitable for protecting specific functional groups.
  • a protecting group may, for instance, be an alcohol protecting group, an amine protecting group or a carboxylic acid protecting group.
  • the invention provides a process for producing an organic compound comprising an 18 F atom, which process comprises treating a precursor organic compound comprising a -CY2X group with:
  • an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein
  • X is a leaving group
  • each Y is independently selected from F, CI, Br and H.
  • the [ 18 F]fluoride and the activator do not usually come from the same compound (e.g. from a single salt).
  • Components (i) and (ii) are typically added separately.
  • the organic compound comprising an 18 F atom is generally an organic compound wherein the X in the -CY 2 X group of the precursor organic compound has been replaced with 18 F.
  • the organic compound comprising an 18 F atom or the precursor organic compound may be any suitable organic compound such as those discussed below.
  • the precursor organic compound is typically a small organic compound, for instance having a molar mass of less than or equal to 1000 gmol "1 , often less than or equal to 600 gmol "1 .
  • X may be any suitable leaving group. Leaving groups are well known to the skilled person and include those groups which are susceptible to being replaced by another group, typically by nucleophilic substitution.
  • X is typically a group selected from perfluoroalkylsulfonate groups (for instance triflate and nonaflate), sulfonate groups (for instance tosylate or mesylate), halide groups (for instance fluoride, chloride, bromide or iodide), carboxylate groups (for instance acetate or trifluoroacetate), nitrate groups and phosphate groups (for instance phosphate or alkylphosphate).
  • X is a halide group.
  • the X is a leaving group which is CI, Br or I.
  • X is often CI or Br.
  • Each Y is typically independently selected from F and H.
  • the -CY 2 X group is often -CF 2 X or -CFHX.
  • X is a leaving group which is usually a halide.
  • X in this embodiment is CI, Br or I, for instance CI or Br.
  • the precursor organic compound is often a compound of formula: R-CFXY; R-O-CFXY; R-N(R')-CFXY; R-S-CFXY; R-Se-CFXY; R-Te-CFXY; or a salt thereof, wherein: X is a leaving group, typically CI, Br or I; Y is F, CI, Br or H; R is a substituted or unsubstituted Ci- 60 organic group, typically a substituted or unsubstituted Ci-40 organic group; and R' is H or a substituted or unsubstituted Ci-40 organic group, which may optionally be bonded together with R to form a ring.
  • the precursor compound may be a compound of formula R-O-CFXY; R-N(R')-CFXY; R-S-CFXY; R-Se-CFXY; R-Te-CFXY; or a salt thereof, wherein: X is a leaving group, typically CI, Br or I; Y is F, CI, Br or H; R is a substituted or unsubstituted Ci-40 organic group; and R' is H or a substituted or unsubstituted Ci-40 organic group, which may optionally be bonded together with R to form a ring.
  • the precursor organic compound is a compound of formula: R-CFXY; R-O- CFXY; R-S-CFXY; or a salt thereof, wherein: X is CI, Br or I; Y is F or H; and R is a substituted or unsubstituted Ci-40 organic group.
  • the precursor compound may be a compound of formula R-O-CFXY or a salt thereof.
  • the precursor compound may be a compound of formula R-S-CFXY or a salt thereof.
  • X is CI and Y is F or H; or X is Br and Y is F.
  • the -CFXY group is typically -CF 2 I, - CF 2 Br, -CF2CI, -CFHI, -CFHBr or -CFHC1. It may for instance be -CF 2 Br or -CFHC1.
  • the process of the invention applies very generally to a wide range of compounds and R may therefore be a wide range of organic groups.
  • R may be any C1-60 organic group (which may be substituted or unsubstituted) and is typically a C1-60 organic group comprising one or more aryl or heteroaryl rings.
  • R may be any Ci-40 organic group (which may be substituted or unsubstituted) and is typically a Ci-40 organic group comprising one or more aryl or heteroaryl rings.
  • R may be a substituted or unsubstituted C3-40 organic group, a substituted or unsubstituted C5-35 organic group or a substituted or unsubstituted Cio-30 organic group.
  • R typically comprises one to four aryl or heteroaryl groups. Substituted organic groups are themselves organic groups. Often, the Ci- 40 organic group is unsubstituted.
  • R may alternatively be H in some cases. Often, R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
  • the aryl group or heteroaryl group is typically substituted as defined above.
  • R may for instance be an aryl or heteroaryl group which is substituted with one or more aryl or heteroaryl groups, each of which may themselves be substituted or unsubstituted. As mentioned above, the identity of R is not particularly limited. Often, R is substituted or unsubstituted biphenyl.
  • R' may be any Ci-40 organic group (which may be substituted or unsubstituted) and is typically a Ci-40 organic group comprising one or more aryl or heteroaryl rings.
  • R' may be a substituted or unsubstituted C3-40 organic group, a substituted or unsubstituted C5-35 organic group or a substituted or unsubstituted Cio-30 organic group.
  • R' typically comprises one to four aryl or heteroaryl groups. Substituted organic groups are themselves organic groups. Often, the Ci-40 organic group is unsubstituted.
  • R' may for instance be H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R' is typically H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl.
  • R' is often unsubstituted Ci-6 alkyl or unsubstituted aryl.
  • R' may be H, methyl, ethyl or phenyl.
  • the organic compounds comprising an 18 F atom are often intended for use in medical imaging, for instance PET imagining.
  • the organic compound comprising an 18 F atom is often suitable for administration to a human subject and optionally suitable for use in PET imaging.
  • the invention provides a compound comprising an 18 F atom for use in PET imaging, or a method of PET imaging comprising administering a compound comprising an 18 F atom as defined herein to a patient.
  • the precursor organic compound may, for instance, be a precursor to a pharmaceutical compound wherein an F atom in the pharmaceutical compound has been replaced with X as defined herein, or a protected version thereof.
  • the pharmaceutical compound comprises an F atom (which can be replaced by X). Lists of pharmaceutical compounds are readily available to the skilled person, for instance in the form of pharmacopoeias.
  • a prostaglandin e.g.
  • a protected version of the precursor compound is the precursor compound wherein one or more groups within the precursor compound have been protected.
  • groups within a starting material i.e. the precursor organic compound
  • alcohol, amine and carboxylic acids in the precursor compound are protected using well known protecting groups.
  • alcohol protecting groups include substituted or unsubstituted C 1-10 alkyl, substituted or unsubstituted -C(0)-C 1-10 alkyl, substituted or unsubstituted -C 1-10 alkylene-O- C 1-10 alkyl optionally wherein the C 1-10 alkylene group and C 1-10 alkyl group may be bonded together to form a ring, and substituted or unsubstituted tri(C 1-10 alkyl) silyl.
  • carboxylic acid protecting group examples include substituted or unsubstituted C 1-10 alkyl, substituted or unsubstituted -C(0)-C 1-10 alkyl, and substituted or unsubstituted tri(C 1 -10 alkyl) silyl.
  • Examples of amine protecting group include substituted or unsubstituted C 1-10 alkyl, substituted or unsubstituted -C(0)-C 1-10 alkyl, substituted or unsubstituted -C(0)-0-C 1-10 alkyl, substituted or unsubstituted -S(0)2-aryl.
  • a protecting group is selected from methyl, ethyl, tert-butyl, benzyl, carbobenzyloxy (Cbz), p-methoxybenzyl carbonyl (Moz), tert-butyloxycarbonyl (Boc), 9- fluorenylmethyloxycarbonyl (FMOC), acetyl and benzoyl.
  • the process of the invention often further comprises deprotecting the produced compound comprising an 18 F atom.
  • Deprotection may be performed by any suitable method. Such methods are well known to the skilled person. Often, removing one or more protecting groups from (deprotecting) the compound comprising an 18 F atom comprises performing hydrolysis on the compound. For instance, the process may further comprise treating the compound comprising an 18 F atom with an aqueous acid, for instance aqueous HI, HBr or HC1.
  • an aqueous acid for instance aqueous HI, HBr or HC1.
  • the precursor organic compound often does not comprise a a carboxylic acid group or a hydroxyl group.
  • the process of the invention may be performed as a no-carrier added radiofluorination process.
  • substantially no 19 F " is added during the reaction.
  • no more than 1 mmol of 19 F " is added during the reaction or no more than 1 ⁇ of 19 F " is added during the reaction.
  • some 19 F " may already present during the reaction for instance from the precursor compound or by substitution of existing 19 F atoms and "added” in this context means added from an external source.
  • [ 18 F]fluoride is commercially available or may be manufactured using a cyclotron or linear accelerator, for instance by bombardment of 18 0 with high energy protons.
  • the [ 18 F]fluoride is typically added in the form of a salt.
  • the [ 18 F]fluoride salt is typically a salt of
  • [ 18 F]fluoride with an alkali metal cation or a quaternary ammonium cation for instance Li 18 F, Na 18 F, K 18 F, Rb 18 F, [NMe 4 ] 18 F, [NEt 4 ] 18 F or [ Bu 4 ] 18 F.
  • the salt also contains a complexing agent, for instance a crown ether or a cryptand.
  • the fluoride is added as an alkali metal [ 18 F]fluoride salt complexed with a cryptand.
  • Examples of cryptands include aminopolyether 2.2.2 (K 222 ), which is
  • the addition of such a cryptand enables the fluoride ion 18 F " to be solubilized in a polar aprotic solvent, for instance acetonitrile or DMF. It also enables the formation of a 'naked fluoride ion' as a KF-K222 complex. In one embodiment, therefore, the source of 18 F " is a K 18 F-K 2 22 complex.
  • the source of 18 F " may be [ 18 F]TEAF (tetraethylammonium fluoride),
  • [ 18 F]TBAF tetrabutylammonium fluoride
  • [ 18 F]CsF tetrabutylammonium fluoride
  • [ 18 F]HF tetrabutylammonium fluoride
  • the organic compound comprising an 18 F atom is often a pharmaceutical compound or a protected version thereof.
  • the pharmaceutical compound may be as defined above, and the protecting groups may be as defined above.
  • the pharmaceutical compound in its unradiolabelled state often comprises a group selected from -CF 3 , -CHF2, -O-CF3, -O- CHF2, -S-CF3 and -S-CHF2.
  • the pharmaceutical compound i.e. the compound from which the precursor organic compound, or the organic compound comprising the 18 F atom, is derived
  • the pharmaceutical compound is celecoxib, riluzole, tiflorex, fenfluramine, fluoxetine, efavirenz, sorafenib, nilotinib, aprepitant, tripanavar, travoprost, dutasteride, sitagliptin, cinacalcet, nitisinone, trifluridine, zardaverine, riodipine, pantaprazole, garenoxacin, roflumilast, celikalim, flutiorex, toltrazuril, flomoxef sodium, or a pharmaceutically acceptable salt thereof.
  • pharmaceutically acceptable salt refers to a salt which is tolerated in a clinical setting.
  • examples of pharmaceutically acceptable salts includes salts derived by addition of an acid selected from acetic acid, adipic acid, benzenesulfonic acid, carbonic acid, citric acid, ethanesulfonic acid, formic acid, hydrobromic acid, hydrochloric acid, lactic acid, lauric acid, maleic acid, methanesulfonic acid, nitric acid, oxalic acid, phosphoric acid, salicylic acid, succinic acid, and sulfuric acid.
  • an acid selected from acetic acid, adipic acid, benzenesulfonic acid, carbonic acid, citric acid, ethanesulfonic acid, formic acid, hydrobromic acid, hydrochloric acid, lactic acid, lauric acid, maleic acid, methanesulfonic acid, nitric acid, oxalic acid, phosphoric acid, salicylic acid
  • references to "salt” in general include references to salts formed with any acid (for instance as defined herein) or with any anion (for instance as defined for the activator).
  • the process of the invention may further comprise using the compound in a method of PET imaging.
  • the activator comprises silver, gold, copper or platinum.
  • the activator may comprise elemental silver, gold, copper or platinum, i.e. silver, gold, copper or platinum metal, or it may comprise a compound which comprises silver, gold, copper or platinum. If the activator comprises an elemental metal, it may be in the form of pellets, a mesh or a powder.
  • the activator comprises a silver compound, a gold compound, a copper compound or a platinum compound. More preferably the activator comprises a silver compound or a gold compound. Most preferably, the activator is, or comprises, a silver compound.
  • the activator comprises a silver, gold, copper or platinum compound
  • it may be a covalent compound, an organometallic compound or a salt.
  • the compound is a salt.
  • the compound is typically soluble in organic solvents.
  • the compound may have a solubility of greater than or equal to 1 mmol/L in dichloromethane.
  • the activator may therefore comprise a silver salt, a gold salt, a copper salt or a platinum salt.
  • the metal may be in any oxidation state.
  • the activator may for instance comprise a silver (I) salt, a silver (II) salt, a silver (III) salt, a gold (I) salt, a gold (III) salt, a copper (I) salt, a copper (II) salt, a platinum (II) salt or a platinum (IV) salt.
  • the activator comprises a silver (I) salt or a gold (I) salt.
  • the activator salt typically comprises the metal as the cation and an anion. The anion is often the conjugate base of a strong acid.
  • the anion may be selected from anions of formula (-OS(0) 2 Z)-, (-S(0) 2 Z)-, (-OC(O)Z) " , triflate (OS0 2 CF 3 ) -, triflyl (S0 2 CF 3 ) " triflimide (N(S0 2 CF 3 ) 2 ) " , oxide, fluoride, chloride, bromide, iodide, nitrate, perchl orate, carbonate, nonaflate (OS0 2 (CF 2 ) 3 CF 3 ) " , fluorosulfonate (OS0 2 F) " , tosylate (OS0 2 -p- C 6 H 4 CH 3 )-, mesylate (OS0 2 CH 3 ) _ , pivalate (OOCC(CH 3 ) 3 ) _ , acetate, trifluoroacetate
  • the activator comprises:
  • a silver salt selected from silver triflate (AgOS0 2 CF 3 ), silver triflyl (AgS0 2 CF 3 ), silver triflimide (AgN(S0 2 CF 3 ) 2 ), silver oxide (Ag 2 0), silver fluoride (AgF), silver chloride (AgCl), silver bromide (AgBr), silver iodide (Agl), silver nitrate (AgN0 3 ), silver perchlorate (AgC10 4 ), silver carbonate (Ag 2 C0 3 ), silver nonaflate (AgOS0 2 (CF 2 ) 3 CF 3 ), silver fluorosulfonate (AgOS0 2 F), silver tosylate (AgOSC -p-CeFLtCFb), silver mesylate
  • AgOS0 2 CH 3 silver pivalate (AgOOCC(CH 3 ) 3 ), silver acetate (AgOOCCH 3 ), silver trifluoroacetate (AgOOCCF 3 ), and silver tetrafluorob orate (AgBF4);
  • a gold salt selected from gold triflimide ((Ph 3 P)Au(N(S0 2 CF 3 ) 2 ), triphenylphosphine gold triflimide ((Ph 3 P)Au(N(S0 2 CF 3 ) 2 ), (2-di-tert-butylphosphinobiphenyl) gold triflimide (JohnPhosAu(N(S0 2 CF 3 ) 2 ) triphenylphoshine gold chloride ((Ph 3 P)AuCl), triethylphosphine gold chloride ((Et 3 P)AuCl), l,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene gold chloride ((IPr)AuCl), methyl (triphenylphospine) gold ((Ph 3 P)AuMe); or
  • a copper salt selected from copper (I) triflate (CuOS0 2 CF 3 ), copper (II) triflate (Cu(OS0 2 CF 3 ) 2 ), tetrakis(acetonitrile) copper(I) triflate (Cu(OS0 2 CF 3 ).4MeCN), and tetrakis(pyridine) copper(II) trilfate (Cu(OS0 2 CF 3 ) 2 .4Pyr).
  • the activator comprises a silver (I) salt selected from silver (I) triflate
  • the salt is silver (I) triflate
  • the activator typically consists of, or consists essentially of (e.g. greater than 95 wt%), said compound comprising silver, gold, copper or platinum or said elemental silver, gold, copper or platinum.
  • the amount of the activator is from 0.05 to 20 equivalents of the precursor organic compound. Often, similar amounts of activator and precursor organic compound are used during the process. For instance, the amount of the activator may be from 0.5 to 4 equivalents of the precursor organic compound.
  • the molar ratio activator: precursor organic compound is preferably from 2: 1 to 1 :2. In some cases, the molar ratio is about 1 : 1.
  • the concentration of the precursor organic compound may be any suitable value, for instance from 0.01 M to 1 M.
  • the concentration of the activator compound may be any suitable value, for instance from 0.01 M to 1 M.
  • the concentration of the activator may be from 0.01 M to 0.6 M, preferably from 0.1 M to 0.4 M.
  • [ 18 F]fluorination to occur at surprisingly low temperatures avoiding side reactions and maintaining high specificity.
  • the process is carried out at a temperature of from 20°C to 100°C. Often, the temperature is greater than 30°C or greater than 40°C.
  • the process is carried out at a temperature of from 40°C to 90°C, more preferably from 50°C to 80°C. The temperature may, for instance, be from 55°C to 65°C.
  • the process of the invention is typically carried out for from 10 minutes to 2 hours, for instance for about 30 minutes.
  • the process of the invention is usually carried out in the presence of a solvent.
  • the process often comprises treating a composition comprising a precursor organic compound comprising a -CY 2 X group and a solvent with:
  • an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein:
  • X is a leaving group
  • each Y is independently selected from F, CI, Br and H.
  • the process of the invention may be carried out in the presence of any suitable solvent.
  • solvents examples include water, alcohol solvents (such as methanol, ethanol, n-propanol, isopropanol and n-butanol), ether solvents (such as dimethylether, diethylether and tetrahydrofuran), ester solvents (such as ethyl acetate), carboxylic acid solvents (such as formic acid and ethanoic acid), ketone solvents (such as acetone), amide solvents (such as dimethylformamide and diethylformamide), amine solvents (such as triethylamine), nitrile solvents (such as acetonitrile), sulfoxide solvents (dimethylsulfoxide), hydrocarbon solvents (such as hexane, cyclohexane and benzene) and halogenated solvents (such as
  • dichloromethane DCM
  • dichloroethylene DCE
  • chloroform chlorobenzene
  • the solvent is a non-coordinating solvent, e.g. a solvent which does not comprise an -OH group.
  • the solvent may be any of those listed above except for water, an alcohol solvent or a carboxylic acid solvent.
  • a halogenated solvent is present.
  • halogenated solvents include benzotri chloride, bromoform, bromomethane, carbon tetrachloride, chlorobenzene, chlorofluorocarbon, chloroform, chlorom ethane, 1, 1- dichloro-l-fluoroethane, 1, 1-dichloroethane, 1,2-dichloroethane, 1, 1-dichloroethene, 1,2- dichloroethene, dichloromethane, diiodomethane, haloalkane, halomethane,
  • the solvent is a halogenated solvent which is dichloromethane (DCM) or dichloroethylene (DCE), which may be 1, 1-dichloro
  • the concentration of the [ 18 F]fluoride is usually relatively low, as is typical during radiochemistry.
  • the concentration of [ 18 F]fluoride is typically less than 1 mM, less than 1 ⁇ , or less than 1 nM.
  • the concentration of [ 18 F]fluoride may be from 1 pM to 1 mM, or lpM to 1 nM.
  • the activator comprises silver (I) triflate
  • the process of the invention may comprise adding from 0.01 to 0.1 mmol of the precursor organic compound to a container comprising [ 18 F]KF/K 222 and from 0.01 to 0.1 mmol AgOTf in from 100 to 1000 DCM or DCE.
  • the mixture is allowed to stir at a temperature from 40°C to 80°C for 10 to 1000 minutes, optionally after which time the reaction is quenched by the addition of EtOH/H 2 O.
  • the process is conducted in an automated synthesizer.
  • the automated synthesizer may be any suitable automated synthesizer, as are well known to the skilled person.
  • Automated synthesizers may include one or more means for performing the process of the invention.
  • an automated synthesizer may comprise one or more of (i) a means for mixing the reagents used in the process of the invention, (ii) a means for heating the mixed reagents of the invention and (iii) means for isolating the compound comprising an 18 F atom.
  • Such automated synthesizers may be used for the production of PET ligands comprising an 18 F atom.
  • the automated synthesizer may be suitable for use in a clinical setting, for instance in a imaging centre equipped with PET imaging and/or scanning apparatus.
  • An automated synthesizer may comprise one or more reagents used in the process of the invention.
  • the automated synthesizer may be pre-loaded with one or more reagents, for instance an activator as described herein or a precursor organic compound as described herein.
  • the process of the invention may be conducted in an automated synthesizer, which process further comprises loading the automated synthesizer with one or more reagents.
  • the reagents may be loaded into the automated synthesizer by inserting a pre-packaged amount of the reagent, for instance in the form of a capsule.
  • the process of the invention may further comprise inserting a pre-packaged sample of an activator as defined herein or a precursor organic compound as defined herein into an automated synthesizer.
  • the process of the invention is useful for producing radiolabelled pharmaceutical compounds as described above.
  • the invention also allows the production of precursors for useful reagents for performing -CF 2 18 F trifluoromethylation, and particularly Umemoto reagents (Zhang, Org. Biomol. Chem., 2014, 12, 6580-6589).
  • the precursor organic compound is a compound of formula (1) or a salt thereof,
  • Q is O, R', S, Se or Te, typically S, Se or Te;
  • X is CI, Br or I
  • Y is F, CI, Br or H; each R A is independently a group selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted C 3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C 1-10 alkylthio, aryl
  • R' is H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl; and each n is independently selected from 0, 1, 2, 3 and 4.
  • [ 18 F]fluorinated compounds produced from compounds of formula (1) can easily be oxidised to produce trifluoromethylation agents such as Umemoto reagents.
  • the process further comprises oxidising a compound of formula (1) or a salt thereof to produce a compound of formula (3) or a salt thereof:
  • R A , n and Q are as defined for formula (1).
  • Compounds of formula (3) herein are cationic and will be accompanied by an anion.
  • the anion may be any suitable anion, for instance one of the anions in the silver (I) salts defined herein. Often the anion is
  • Q is preferably S in formulae (1) and (3).
  • Y is typically F or H in formulae (1) and (3).
  • X and Y may be as further defined above.
  • Each n is typically 0, 1 or 2. Preferably each n is 0 or 1.
  • each R A is independently a group selected from unsubstituted C 1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C2-10 alkynyl, unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl, wherein two or more R A groups may be bonded together to form one or more rings.
  • n are 0 and the compound of formula (1) is unsubstituted.
  • the organic precursor compound may be a compound of formula (la) or a salt thereof
  • Q is O, S, Se or Te (usually S, Se or Te), preferably S, and X is CI, Br or I.
  • the invention also provides the use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom as defined herein.
  • an activator as defined herein as an activator in [ 18 F]fluorination of a precursor organic compound by halogen exchange.
  • the activator may be as defined above.
  • the activator comprises a silver (I) salt selected from silver (I) triflate (AgOS0 2 CF 3 ), silver triflimide (AgN(S0 2 CF 3 ) 2 ), silver (I) trifluoroacetate (AgOOCCF 3 ) and silver (I) tetrafluorob orate (AgBF4). More preferably, the activator comprises silver (I) triflate (AgOS0 2 CF 3 ).
  • kit for [ 18 F]radiolabelling an organic compound which kit comprises:
  • an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum;
  • the activator may be as further defined herein.
  • the precursor organic compound may be as defined herein.
  • the kit is typically in the form of packaging comprising components (i) and (ii), each of which may be present in one or more separate containers. Often, the kit further comprises instructions for carrying out a process as defined herein. The instructions may be written or may be in the form of an electronic data carrier.
  • the process of the invention allows facile radiolabelling of organic compounds such as those described above. This means that samples of radiolabelled compounds having high specific activity can be produced.
  • the invention therefore provides a composition comprising a compound of formula:
  • R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl
  • R' is H, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R and R' may be as further defined herein.
  • the specific activity of the composition is preferably greater than or equal to 70 GBq/ ⁇ . In some cases, the specific activity of the composition is greater than or equal to 80
  • the compound in the composition has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
  • the process of the invention also allows access to [ 18 F]radiolabelled compounds which have not been produced before.
  • the invention therefore provides a compound, which compound has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
  • the invention also provides a compound of formula (2) or formula (3) or a salt of a compound of formula (2) or formula (3),
  • Q is O, NR', S, Se or Te, preferably S, Se or Te;
  • each R A is independently a group selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted C 3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di( C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C 1-10 alkylthio, arylthio, sulfonyl,
  • R' is H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl; and each n is independently selected from 0, 1, 2, 3 and 4.
  • compounds of formula (3) are cationic and may have any suitable anion, for instance those defined for salt activators (e.g. tetrafluorob orate or triflate).
  • each R A is independently a group selected from unsubstituted C 1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C 2- 10 alkynyl, unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl, wherein two or more groups may be bonded together to form one or more rings.
  • the compound of the invention is:
  • the salt may comprise an anion as defined herein, for instance triflate or tetrafluorob orate.
  • Compounds of formula (3) may be referred to as Umemoto reagents and are useful as electrophilic sources of CF 2 18 F. These compounds can be reached by oxidising compounds of formula (2) to cause ring closure. The process may therefore further comprise producing and using compounds of formula (3).
  • the invention also provides a process for producing an organic compound comprising a -CF 2 18 F group, which process comprises:
  • Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
  • each R A is independently a group selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted C 3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C 1-10 alkylthio, arylthio, sulfonyl,
  • each n is independently selected from 0, 1, 2, 3 and 4;
  • Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
  • each R A is independently a group selected from substituted or unsubstituted C 1-20 alkyl, substituted or unsubstituted C 2-20 alkenyl, substituted or unsubstituted C 2-20 alkynyl, substituted or unsubstituted C 3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C 1-10 alkylamino, di(C 1-10 )alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C 1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C 1-10 alkylthio, arylthio, sulfonyl,
  • each n is typically 0, 1 or 2.
  • each n is 0 or 1.
  • each R A is independently a group selected from unsubstituted C 1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C2-10 alkynyl,
  • the reactant organic compound is typically a nucleophilic organic compound, i.e. a compound suitable for nucleophilic substitution of the cationic tricylic sulfur species.
  • the reactant organic compound is oftent an organic compound comprising an alkyne group, an alkene group, a 1,3-diketone group, an aryl group, a boronic acid group or an amine group.
  • Step (b) of forming compound of formula (3) typically comprises treating the compound of formula (2) with a compound such as triflic anhydride (trifluoromethanesulfonic anhydride, 0(S0 2 CF 3 ) 2 ).
  • Step (c) of trifluoromethylating a reactant organic compound by treating it with the compound of formula (3) typically comprises mixing the reactant organic compound and the compound of formula (3) in a solvent and optionally heating the mixture.
  • N-bromosuccinimide N-bromosuccinimide
  • yields can be increased by the use of the following conditions: to a V-vial containing [ 18 F]KF/K222 and AgOTf (0.08 mmol) is added substrate (0.04 mmol) in DCE (300 ⁇ L). This mixture is allowed to stir at 60 °C for 20 minutes, after which time the reaction is quenched the addition of EtOH/FbO (9: 1, 500 ⁇ L).
  • reaction was performed with and without the silver triflate confirming the importance of the activator in the halogen exchange radiofluorination.
  • the metal catalysts were screened showing that a wide range of activators can be used.
  • the reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor aryl compounds was found to be possible.
  • the activators were screened.
  • the activator, solvent and temperature were screened.
  • the reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluonnation of electron rich and electron poor substrates was found to be possible.
  • the reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor substrates was found to be possible.
  • a solvent screen was performed which demonstrated that non-coordinating solvents such as DCM and DCE are preferred.
  • a screen of metal activators was performed.
  • the thermal reaction was performed in a number of solvents for comparison.
  • the reaction was performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor substrates was found to be possible.
  • COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) celecoxib was successfully [ 18 F]radiolabelled using the process of the invention at 60°C.
  • a protected precursor comprising a -CF 2 Br group was prepared and this was converted by the process of the invention at two different temperatures.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a process for producing an organic compound comprising an 18F atom, which process comprises treating a precursor organic compound comprising a –CY2X group with: (i) [18F] fluoride; and (ii) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum wherein: X is a leaving group; and each Y is independently selected from F, Cl, Br and H. Also described is the use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom according to the invention. A kit, composition and compound are also described.

Description

FLUORINATION PROCESS
FIELD OF THE INVENTION
The present invention relates to a process for producing an organic compound comprising an 18F atom. The present invention also relates to the use of activators in the [18F]radiolabelling of organic compounds, kits comprising activators, compositions comprising radiolabelled compounds and [18F]radiolabelled compounds.
BACKGROUND OF THE INVENTION
Positron Emission Tomography (PET) is a non-invasive quantitative imaging technology assessing biological and biochemical processes in living subjects. This imaging modality enhances understanding of disease states and drug activity during both preclinical and clinical drug development. The established value of PET for clinical applications combined with continuous technological advances has recently stimulated research activity within the academic sector, and has added strength and stability to institutions involved in imaging technologies. For a large number of studies, 18F is the preferred positron-emitting
radioisotope due to its advantageous properties (a radioactive half-life of 109.771 minutes allowing for imaging durations of up to 10 hours, 97% positron emission, positron energy), the extensive use of 2-deoxy-2-[18F]fluoroglucose ([18F]FDG) in the clinic, and the importance of fluorine substitution in the context of drug discovery. The success of PET and the increasing interest in [18F]radiochemistry recently led to creative methods to incorporate 18F into molecules of increasing complexity. Despite these advances, clinically useful radiotracers lie within a narrow accessible space, with [18F]fluoroalkanes and
[18F]fluoroarenes at the forefront. Many potentially high value PET [18F]labelled tracers and drugs lie outside this radiochemical space, and the ability to test tracers not amenable to traditional [18F]labelling intervention would be a major boost for PET imaging. Medicinal chemists would immediately benefit from a more diverse range of 18F-tags to perform in vivo studies that could inform the selection of leads for further optimization earlier in the drug discovery pipeline. Drug developers employ routinely di- and trifluoromethyl ether and thioether substitution to tune conformation on demand, or modulate physicochemical parameters such as lipophilicity. Examples of pharmaceutical drugs that have directly benefited from these substitutions are riluzole (an OCF3 containing 2-amino benzothiazole and the first drug approved for the treatment of amyotropic lateral sclerosis) and tiflorex (an SCF3 substituted 2-phenylethylamine which possesses anorectic activity). The prospect of preparing [18F]labelled aryl-CF3, -OCF3, -OCHF2, -SCF3 and -SCHF2 in high specific activity applying a common methodology is exciting for drug and radiotracer development.
Radiochemists have employed halogen exchange [18F]fluorination for many years; alkyl halides and halogenated arenes activated by an electron withdrawing group (e.g. N02) respond to halex [18F]fluorination. However, complications may arise from undesired displacement of the activating group itself. The method was applied to convert 2- and 4- chloropyridines to [18F]fluorinated analogues but has met with limited success for RCF2X precursors since the presence of two a-fluorines severely inhibits nucleophilic substitution. Harsh reaction conditions permit access to [18F]aryl-CF3, but the low radiochemical yields and specific activities implied that this chemistry has prohibitively narrow applicability. It is therefore greatly desirable to develop a new method for applying halogen exchange
[18F]fluorination to R-CF2X and R-CFHX precursors under mild reaction conditions which allows access to important [18F]motifs currently not within reach. SUMMARY OF THE INVENTION
It has surprisingly been found that the use of an activator allows [18F]fluorination through halogen exchange to reach a wide range of compounds comprising a trihalomethyl or dihalomethyl group, particularly -CF2 18F and -CFH18F. This approach of metal-based halogen exchange chemistry has never been considered as a generic activation manifold to promote halogen exchange [18F]fluorination. The inventors have found that
[18F]radiolabelled compounds comprising a -CF2 18F or related group can be produced under very mild conditions. This enables the production of [18F]radiolabelled samples with high specific activities.
The invention therefore provides a process for producing an organic compound comprising an 18F atom, which process comprises treating a precursor organic compound comprising a -CY2X group with:
(i) [18F] fluoride; and
(ϋ) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein:
X is a leaving group; and each Y is independently selected from F, CI, Br and H.
The invention also provides the use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom as defined herein.
The invention also provides a kit for [18F]radiolabelling an organic compound, which kit comprises:
(i) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum; and (ii) a precursor organic compound comprising a -CY2X group, wherein X is a leaving group and each Y is independently selected from F, CI, Br and H.
The invention also provides a composition comprising a compound of formula:
R-CF2 18F;
R-CHF18F;
R-0-CF2 18F;
R-0-CHF18F;
R-N(R')-CF2 18F;
R-N(R')-CHF18F
R-S-CF2 18F; or
R-S-CHF18F;
or a pharmaceutically acceptable salt thereof;
and having a specific activity of greater than or equal to 50 GBq/μιηοΙ,
wherein:
R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; and R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
The invention also provides a compound which is [18F]sorafenib, [18F]aprepitant,
[18F]tripanavar, [18F]dutasteride, [18F]dutasteride, [18F]travoprost, [18F]sitagliptin,
[18F]cinacalcet, [18F]notisinone, [18F]trifluridine, [18F]zardaverine, [18F]riodipine, [18F](-)- pantaprazole, [18F]garenoxacin, [18F]roflumilast, [18F]celikalim, [18F]riluzole, [18F]tiflorex, [18F]toltrazuril or [18F]flomoxef sodium, or a pharmaceutically acceptable salt thereof, or a [18F]radiolabelled Umemoto reagent.
DETAILED DESCRIPTION OF THE INVENTION
Definitions The term "organic group", as used herein, refers to a group derived by removing a hydrogen atom from an organic compound. An organic compound is typically a compound comprising a hydrogen atom bonded to a carbon atom, but may also include compounds comprising a covalent bond between carbon and another atom. The term organic compound is well known in the art. The term "C1-60 organic group" refers to an organic group comprising from 1 to 60 carbon atoms. Likewise, the term "Ci-40 organic group" refers to an organic group comprising from 1 to 40 carbon atoms. For instance, an example of a C10 organic group is a group derived by removing a hydrogen atom from an organic compound which contains 10 carbon atoms. Often, a C1-60 organic group is a substituted or unsubstituted aryl group or a substituted or unsubstituted hetroaryl group. The term "alkyl group", as used herein, refers to a straight or branched chain saturated hydrocarbon radical. Typically an alkyl group is C1-20 alkyl, or C1-10 alkyl, for example methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl (including straight or branched chain isomers thereof), or Ci-6 alkyl, for example methyl, ethyl, propyl, butyl, pentyl or hexyl (including straight or branched chain isomers thereof), or C1-4 alkyl, for example methyl, ethyl, i-propyl, n-propyl, t-butyl, s-butyl or n-butyl. When an alkyl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or
unsubstituted C2-20 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, formyl, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e. thiol, -SH), C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester. Examples of substituted alkyl groups include haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl and alkaryl groups. The term alkaryl, as used herein, pertains to a C1-20 alkyl group in which at least one hydrogen atom has been replaced with an aryl group. Examples of such groups include, but are not limited to, benzyl (phenylmethyl, PI1CH2-), benzhydryl (Ph2CH-), trityl (triphenylmethyl, Ph3C-), and phenethyl (phenyl ethyl, Ph-CH2CH2-).
Typically a substituted alkyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
The term "perfluoroalkyl", as used herein, refers to a group which is a straight or branched chain saturated perfluonnated hydrocarbon radical. For example, a perfluoroalkyl group may be have from a to 12 carbon atoms. "Perfluonnated" in this context means completely fluorinated such that there are no carbon-bonded hydrogen atoms replaceable with fluorine. Examples of C4-12 perfluoro alkyl groups are trifluoromethyl (Ci), pentafluoroethyl (C2), hetptafluoropropyl (C3), perfluorobutyl (C4) (for instance including perfluoro-«-butyl, perfluoro-sec-butyl and perfluoro-tert-butyl), perfluoropentyl (C5), perfluorohexyl (C6), perfluoroheptyl (C7), perfluorooctyl (C8), perfluorononyl (Cs>), perfluorodecyl (Cio), perfluoroundecyl (Cn) and perfluorododecyl (C12), including straight chained and branched isomers thereof.
The term "alkenyl", as used herein, refers to a linear or branched chain hydrocarbon radical comprising one or more double bonds. An alkenyl group may be a C2-2o alkenyl group, a C2- io alkenyl group or a C2-6 alkenyl group. Examples of C2-2o alkenyl groups include those related to C2-2o alkyl groups by the insertion of one or more double bonds. Alkenyl groups typically comprise one or two double bonds. The alkenyl groups referred to herein may be substituted or unsubstituted, as defined for alkyl groups above.
The term "alkynyl", as used herein, refers to a linear or branched chain hydrocarbon radical comprising one or more triple bonds. An alkynyl group may be a C2-2o alkynyl group, a C2-10 alkynyl group a C2-6 alkynyl group. Examples of C2-2o alkynyl groups include those related to C2-2o alkyl groups by the insertion of one or more triple bonds. Alkynyl groups typically comprise one or two triple bonds. The alkynyl groups referred to herein may be substituted or unsubstituted, as defined for alkyl groups above. The term "cycloalkyl group", as used herein, refers to an substituted or unsubstituted alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound. A cycloalkyl group may have from 3 to 25 carbon atoms (unless otherwise specified), including from 3 to 25 ring atoms. Thus, the term "cycloalkyl" includes the sub-classes cycloalkyenyl and cycloalkynyl. Examples of groups of C3-25 cycloalkyl groups include C3-2o cycloalkyl, C3-15 cycloalkyl, C3-10 cycloalkyl, and C3 -7 cycloalkyl. When a C3-25 cycloalkyl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e. thiol, -SH), C1-10 alkylthio, arylthio, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester and sulfonyl.
Typically a substituted cycloalkyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
Examples of C3-25 cycloalkyl groups include, but are not limited to, those derived from saturated monocyclic hydrocarbon compounds, which C3-25 cycloalkyl groups are substituted or unsubstituted as defined above: cyclopropane (C3), cyclobutane (C4), cyclopentane (C5), cyclohexane (C6), cycloheptane (C7), methylcyclopropane (C4), dimethylcyclopropane (C5), methylcyclobutane (C5), dimethylcyclobutane (C6), methylcyclopentane (C6),
dimethylcyclopentane (C7), methylcyclohexane (C7), dimethylcyclohexane (C8), menthane (Cio); unsaturated monocyclic hydrocarbon compounds: cyclopropene (C3), cyclobutene (C4), cyclopentene (C5), cyclohexene (C6), methylcyclopropene (C4), dimethylcyclopropene (C5), methylcyclobutene (C5), dimethylcyclobutene (C6), methylcyclopentene (C6),
dimethylcyclopentene (C7), methylcyclohexene (C7), dimethylcyclohexene (C8); saturated polycyclic hydrocarbon compounds: thujane (Cio), carane (Cio), pinane (Cio), bornane (Cio), norcarane (C7), no inane (C7), norbornane (C7), adamantane (Cio), decalin
(decahydronaphthalene) (Cio); unsaturated polycyclic hydrocarbon compounds: camphene (Cio), limonene (Cio), pinene (Cio); polycyclic hydrocarbon compounds having an aromatic ring: indene (C9), indane (e.g., 2,3-dihydro-lH-indene) (C9), tetraline
(1,2,3,4-tetrahydronaphthalene) (Cio), acenaphthene (C12), fluorene (C13), phenalene (C13), acephenanthrene (C15), aceanthrene (C16), cholanthrene (C20). The term "heterocyclyl group", as used herein, refers to an substituted or unsubstituted monovalent moiety obtained by removing a hydrogen atom from a ring atom of a
heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms. Heterocyclic compounds include aromatic heterocyclic compounds and non-aromatic heterocyclic compounds. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms. When a C3- 20 heterocyclyl group is substituted it typically bears one or more substituents selected from Ci-6 alkyl which is unsubstituted, aryl (as defined herein), cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, aiylamino, diaiylamino, aiylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e. thiol, -SH), C1-10 alkylthio, arylthio, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester and sulfonyl. Typically a substituted C3-20 heterocyclyl group carries 1, 2 or 3 substituents, for instance 1 or 2.
Examples of groups of heterocyclyl groups include C3-20 heterocyclyl, C5-20 heterocyclyl, C3-15 heterocyclyl, C5-15 heterocyclyl, C3 -12 heterocyclyl, C5-12 heterocyclyl, C3 -10 heterocyclyl, C5-10 heterocyclyl, C3-7 heterocyclyl, C5-7 heterocyclyl, and C5-6 heterocyclyl.
Examples of (non-aromatic) monocyclic C3-20 heterocyclyl groups include, but are not limited to, those derived from:
Ni: aziridine (C3), azetidine (C4), pyrrolidine (tetrahydropyrrole) (C5), pyrroline (e.g.,
3-pyrroline, 2,5-dihydropyrrole) (C5), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C5), piperidine (C6), dihydropyridine (C6), tetrahydropyridine (C6), azepine (C7);
Oi: oxirane (C3), oxetane (C4), oxolane (tetrahydrofuran) (C5), oxole (dihydrofuran) (C5), oxane (tetrahydropyran) (C6), dihydropyran (C6), pyran (C6), oxepin (C7);
Si: thiirane (C3), thietane (C4), thiolane (tetrahydrothiophene) (C5), thiane
(tetrahydrothiopyran) (C6), thiepane (C7);
O2: dioxolane (C5), dioxane (C6), and dioxepane (C7);
O3 : trioxane (C6);
N2: imidazolidine (C5), pyrazolidine (diazolidine) (C5), imidazoline (C5), pyrazoline
(dihydropyrazole) (C5), piperazine (C6);
N1O1 : tetrahydrooxazole (C5), dihydrooxazole (C5), tetrahydroisoxazole (C5),
dihydroisoxazole (C5), morpholine (C6), tetrahydrooxazine (C6), dihydrooxazine (C6), oxazine (C6);
N1S1 : thiazoline (C5), thiazolidine (C5), thiomorpholine (C6);
N2O1 : oxadiazine (C6);
O1S1 : oxathiole (C5) and oxathiane (thioxane) (C6); and,
N1O1S1 : oxathiazine (C6).
Examples of substituted (non-aromatic) monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C5), such as
arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C6), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
Examples of C3-20 heterocyclyl groups which are also aryl groups are described below as heteroaryl groups. The term "aryl group", as used herein, refers to a substituted or unsubstituted, monocyclic or poly cyclic (for instance bicyclic) aromatic group which typically contains from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms in the ring portion. Examples include phenyl, naphthyl, indenyl, indanyl, anthracenyl and pyrenyl groups. An aryl group is substituted or unsubstituted. When an aryl group is substituted it typically bears one or more substituents selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e. thiol, - SH), C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester. Typically it carries 0, 1, 2 or 3 substituents. A substituted aryl group may be substituted in two positions with a single Ci-6 alkylene group, or with a bidentate group represented by the formula -X-Ci-6 alkylene, or -X-Ci-6 alkylene-X-, wherein X is selected from O, S and R, and wherein R is H, aryl or C 1-6 alkyl. Thus a substituted aryl group may be an aryl group fused with a cycloalkyl group or with a heterocyclyl group. The term
"aralkyl" as used herein, pertains to an aryl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been substituted with a Ci-6 alkyl group. Examples of such groups include, but are not limited to, tolyl (from toluene), xylyl (from xylene), mesityl (from mesitylene), and cumenyl (or cumyl, from cumene), and duryl (from durene). The term "heteroaryl group", as used herein, refers to a substituted or unsubstituted, monocyclic or polycyclic (for instance bicyclic) aromatic group which typically contains from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms in the ring portion wherein the ring atoms of the group include one or more heteroatoms. Thus, a heteroaryl group is a substituted or unsubstituted monocyclic or polycyclic (for instance bicyclic) heteroaromatic group which typically contains from 6 to 14 atoms, for instance 6 to 10 atoms, in the ring portion including one or more heteroatoms. It is generally a 5- or 6-membered ring, containing at least one heteroatom selected from O, S, N, P, Se and Si. It may contain, for example, 1, 2 or 3 heteroatoms. Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolyl and isoquinolyl. A heteroaryl group may be substituted or unsubstituted, for instance, as specified above for aryl. Typically it carries 0, 1, 2 or 3 substituents.
The term "alkylene group" as used herein, refers to an substituted or unsubstituted bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term "alkylene" includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.
Typically it is C1-10 alkylene, for instance Ci-6 alkylene. Typically it is Ci-4 alkylene, for example methylene, ethylene, i-propylene, n-propylene, t-butylene, s-butylene or n-butylene. It may also be pentylene, hexylene, heptylene, octylene and the various branched chain isomers thereof. An alkylene group may be substituted or unsubstituted, for instance, as specified above for alkyl. Typically a substituted alkylene group carries 1, 2 or 3
substituents, for instance 1 or 2.
In this context, the prefixes (e.g., Ci-4, C1-7, C1-20, C2-7, C3-7, etc.) denote the number of carbon atoms, or range of number of carbon atoms. For example, the term "Ci-4alkylene," as used herein, pertains to an alkylene group having from 1 to 4 carbon atoms. Examples of groups of alkylene groups include Ci-4 alkylene ("lower alkylene"), C1-7 alkylene, C1-10 alkylene and C1-20 alkylene.
Examples of linear saturated C1-7 alkylene groups include, but are not limited to, -(0¾)η- where n is an integer from 1 to 7, for example, -CH2- (methylene), -CH2CH2- (ethylene), -CH2CH2CH2- (propylene), and -CH2CH2CH2CH2- (butylene). Examples of branched saturated C1-7 alkylene groups include, but are not limited
to, -CH(CH3)-, -CH(CH3)CH2-, -CH(CH3)CH2CH2-, -CH(CH3)CH2CH2CH2-, -CH2CH(CH3) CH2-, -CH2CH(CH3)CH2CH2-, -CH(CH2CH3)-, -CH(CH2CH3)CH2-,
and -CH2CH(CH2CH3)CH2-. Examples of linear partially unsaturated C1-7 alkylene groups include, but is not limited to, -CH=CH- (vinylene), -CH=CH-CH2-, -CH2-
CH=CH2-, -CH=CH-CH2-CH2-, -CH=CH-CH2-CH2-CH2-, -CH=CH-CH=CH- , -CH=CH-CH=CH-CH2-, -CH=CH-CH=CH-CH2-CH2-, -CH=CH-CH2-CH=CH-, and -CH=CH-CH2-CH2-CH=CH-. Examples of branched partially unsaturated C1-7 alkylene groups include, but is not limited to, -C(CH3)=CH-, -C(CH3)=CH-CH2-,
and -CH=CH-CH(CH3)-. Partially unsaturated alkylene groups comprising one or more double bonds may be referred to as alkenylene groups. Partially unsaturated alkylene groups comprising one or more triple bonds may be referred to as alkynylene groups (for instance - C≡C-, CH2-C≡C-, and -CH2-C≡C-CH2-). Examples of alicyclic saturated C1-7 alkylene groups include, but are not limited to, cyclopentylene (e.g., cyclopent-l,3-ylene), and cyclohexylene (e.g., cyclohex-l,4-ylene). Examples of alicyclic partially unsaturated C1-7 alkylene groups include, but are not limited to, cyclopentenylene (e.g., 4-cyclopenten-l,3-ylene),
cyclohexenylene (e.g., 2-cyclohexen-l,4-ylene; 3-cyclohexen-l,2-ylene; 2,5-cyclohexadien- 1,4-ylene).
C1-20 alkylene and C1-20 alkyl groups as defined herein are either uninterrupted or interrupted by one or more heteroatoms or heterogroups, such as S, O or N(R") wherein R" is H, Ci-6 alkyl or aryl (typically phenyl), or by one or more arylene (typically phenylene) groups, or by one or more -C(O)- or -C(0)N(R")- groups. The phrase "optionally interrupted" as used herein thus refers to a C1-20 alkyl group or an alkylene group, as defined above, which is uninterrupted or which is interrupted between adjacent carbon atoms by a heteroatom such as oxygen or sulfur, by a heterogroup such as N(R") wherein R" is H, aryl or Ci-C6 alkyl, or by an arylene group, or by a -C(O)- or -C(0)N(R")- group, again wherein R" is H, aryl or Ci-C6 alkyl.
For instance, a C1-20 alkyl group such as n-butyl may be interrupted by the heterogroup N(R") as follows: -CH2N(R")CH2CH2CH3, -CH2CH2N(R")CH2CH3, or -CH2CH2CH2N(R")CH3. Similarly, an alkylene group such as n-butylene may be interrupted by the heterogroup N(R") as follows: -CH2N(R")CH2CH2CH2-, -CH2CH2N(R")CH2CH2-, or -CH2CH2CH2N(R")CH2-. Typically an interrupted group, for instance an interrupted C1-20 alkylene or C1-20 alkyl group, is interrupted by 1, 2 or 3 heteroatoms or heterogroups or by 1, 2 or 3 arylene (typically phenylene) groups. More typically, an interrupted group, for instance an interrupted C1-20 alkylene or C1-20 alkyl group, is interrupted by 1 or 2 heteroatoms or heterogroups or by 1 or 2 arylene (typically phenylene) groups. For instance, a C1-20 alkyl group such as n-butyl may be interrupted by 2 heterogroups N(R") as follows: -CH2N(R")CH2N(R")CH2CH3.
An arylene group is an substituted or unsubstituted bidentate moiety obtained by removing two hydrogen atoms, one from each of two different aromatic ring atoms of an aromatic compound, which moiety has from 5 to 14 ring atoms (unless otherwise specified).
Typically, each ring has from 5 to 7 or from 5 to 6 ring atoms. An arylene group may be substituted or unsubstituted, for instance, as specified above for aryl.
In this context, the prefixes (e.g., C5-20, C6-2o, C5-14, C5-7, C5-6, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C5-6 arylene," as used herein, pertains to an arylene group having 5 or 6 ring atoms. Examples of groups of arylene groups include C5-20 arylene, C6-2o arylene, C5-14 arylene, C6-i4 arylene, C6-io arylene, C5-12 arylene, C5-10 arylene, C5-7 arylene, C5-6 arylene, C5 arylene, and C6 arylene. The ring atoms may be all carbon atoms, as in "carboarylene groups" (e.g., C6-20
carboarylene, C6-i4 carboarylene or C6-io carboarylene).
Examples of C6-2o arylene groups which do not have ring heteroatoms (i.e., C6-2o carboarylene groups) include, but are not limited to, those derived from the compounds discussed above in regard to aryl groups, e.g. phenylene, and also include those derived from aryl groups which are bonded together, e.g. phenyl ene-phenylene (diphenylene) and phenylene-phenylene- phenylene (triphenylene).
Alternatively, the ring atoms may include one or more heteroatoms, as in " heteroaryl ene groups" (e.g., Cs-io heteroarylene).
Examples of C5-10 heteroarylene groups include, but are not limited to, those derived from the compounds discussed above in regard to heteroaryl groups.
As used herein the term "oxo" represents a group of formula: =0
As used herein the term "acyl" represents a group of formula: -C(=0)R, wherein R is an acyl substituent, for example, a substituted or unsubstituted C1-20 alkyl group, substituted or unsubstituted C2-20 alkenyl group, substituted or unsubstituted C2-20 alkynyl group, a substituted or unsubstituted C3-20 heterocyclyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, for instance a substituted or unsubstituted Ci-6 alkyl group. Examples of acyl groups include, but are not limited to, -C(=0)CH3 (acetyl), -C(=0)CH2CH3 (propionyl), -C(=0)C(CH3)3 (t-butyryl), and -C(=0)Ph (benzoyl, phenone). As used herein the term "acyloxy" (or reverse ester) represents a group of
formula: -OC(=0)R, wherein R is an acyloxy substituent, for example, a substituted or unsubstituted C1-20 alkyl group, substituted or unsubstituted C2-20 alkenyl group, substituted or unsubstituted C2-2o alkynyl group, a substituted or unsubstituted C3 -20 heterocyclyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, for instance a substituted or unsubstituted Ci-6 alkyl group. Examples of acyloxy groups include, but are not limited to, -OC(=0)CH3
(acetoxy), -OC(=0)CH2CH3, -OC(=0)C(CH3)3, -OC(=0)Ph, and -OC(=0)CH2Ph.
As used herein the term "ester" (or carboxylate, carboxylic acid ester or oxycarbonyl) represents a group of formula: -C(=0)OR, wherein R is an ester substituent, for example, a substituted or unsubstituted C1-20 alkyl group, substituted or unsubstituted C2-20 alkenyl group, substituted or unsubstituted C2-20 alkynyl group, a substituted or unsubstituted C3-2o heterocyclyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, for instance a substituted or unsubstituted Ci-6 alkyl group. Examples of ester groups include, but are not limited
to, -C(=0)OCH3, -C(=0)OCH2CH3, -C(=0)OC(CH3)3, and -C(=0)OPh.
As used herein the term "amino" represents a group of formula - H2. The term "C1-C10 alkylamino" represents a group of formula - HR' wherein R' is a C1-10 alkyl group, preferably a Ci-6 alkyl group, as defined previously. The term "di(C1-10)alkylamino" represents a group of formula - R'R' ' wherein R' and R' ' are the same or different and represent C1-10 alkyl groups, preferably Ci-6 alkyl groups, as defined previously. The term "arylamino" represents a group of formula -NHR' wherein R' is an aryl group, preferably a phenyl group, as defined previously. The term "diarylamino" represents a group of formula -NR'R' ' wherein R' and R' ' are the same or different and represent aryl groups, preferably phenyl groups, as defined previously. The term "arylalkylamino" represents a group of formula -NR'R" wherein R' is a C1-10 alkyl group, preferably a Ci-6 alkyl group, and R" is an aryl group, preferably a phenyl group.
A halo group is chlorine, fluorine, bromine or iodine (a chloro group, a fluoro group, a bromo group or an iodo group). It is typically chlorine, fluorine or bromine. As used herein the term "amido" represents a group of formula: -C(=0)NR R , wherein R and R are independently amino substituents, as defined for di(C1-10)alkylamino groups. Examples of amido groups include, but are not limited
to, -C(=0) H2, -C(=0) HCH3, -C(=0)N(CH3)2, -C(=0) HCH2CH3,
and -C(=0)N(CH2CH3)2, as well as amido groups in which R and R , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.
As used herein the term "acylamido" represents a group of formula: - R1C(=0)R2, wherein R1 is an amide substituent, for example, hydrogen, a Ci-2oalkyl group, a C3-2o heterocyclyl group, an aryl group, preferably hydrogen or a C1-20 alkyl group, and R2 is an acyl substituent, for example, a Ci-2o alkyl group, a C3 -2o heterocyclyl group, or an aryl group, preferably hydrogen or a Ci-2o alkyl group. Examples of acylamide groups include, but are not limited
Figure imgf000014_0001
and
Figure imgf000014_0002
Thus, a substituted Ci-2o alkyl group may comprise an acylamido substituent defined by the formula
Figure imgf000014_0003
or
Figure imgf000014_0004
R1 and R2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:
Figure imgf000014_0005
succinimidyl maleimidyl phthalimidyl
A C1-10 alkylthio group is a said C1-10 alkyl group, preferably a Ci-6 alkyl group, attached to a thio group. An arylthio group is an aryl group, preferably a phenyl group, attached to a thio group. A C1-20 alkoxy group is a said substituted or unsubstituted Ci-2o alkyl group attached to an oxygen atom. A Ci-6 alkoxy group is a said substituted or unsubstituted Ci-6 alkyl group attached to an oxygen atom. A C1-4 alkoxy group is a substituted or unsubstituted C1-4 alkyl group attached to an oxygen atom. Said Ci-2o, Ci-6 and C1-4 alkyl groups are optionally interrupted as defined herein. Examples of C1-4 alkoxy groups include, -OMe
(methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), - O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy). Further examples of Ci-2o alkoxy groups are -O(Adamantyl), -0-CH2-Adamantyl and -0-CH2-CH2-Adamantyl. An aryloxy group is a substituted or unsubstituted aryl group, as defined herein, attached to an oxygen atom. An example of an aryloxy group is -OPh (phenoxy).
Unless otherwise specified, included in the above are the well known ionic, salt, solvate, and protected forms of these substituents. For example, a reference to carboxylic acid or carboxyl group (-COOH) also includes the anionic (carboxylate) form (-COO"), a salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-^HR^2), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-0"), a salt or solvate thereof, as well as conventional protected forms.
Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and 1-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair- forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or
"isomeric forms").
Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers," as used herein, are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH3, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH2OH. Similarly, a reference to ortho- chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., Ci-7alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
The above exclusion does not pertain to tautomeric forms, for example, keto, enol, and enolate forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime,
thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.
Figure imgf000016_0001
keto enol enolate
Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ¾, 2H (D), and 3H (T); C may be in any isotopic form, including 12C, 13C, and 14C; O may be in any isotopic form, including 160 and 180; and the like, unless otherwise specified. However, reference to an isotope of fluorine refers only to that isotope of fluorine. In particular, reference to 18F includes only 18F. Reference to fluorine without specifying the isotope may refer to 18F or 19F depending on context. Typically, reference to "F" (i.e. without defining the isotope) refers to the 19F, i.e. stable fluorine. Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting known methods, in a known manner. The term "substituted", as used herein, may be as defined above for particular groups, e.g. for alkyl. Thus, the term substituted typically refers to a group substituted with a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, formyl, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, sulfhydryl (i.e. thiol, -SH), C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester. In other instances, the term "substituted" may refer to a group substituted with a group selected from substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, Ci-6 alkylamino, di(Ci-6)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, oxo, halo, carboxy, ester, acyl, acyloxy, Ci-6 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C 1-6 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester. For example, the term "substituted" may refer to a group substituted with a group selected unsubstituted Ci-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl, unsubstituted aryl, unsubstituted heteroaryl, cyano, amino, unsubstituted Ci-6 alkylamino, unsubstituted di(Ci-6)alkylamino, unsubstituted arylamino, unsubstituted diarylamino, unsubstituted arylalkylamino, unsubstituted amido, unsubstituted acylamido, hydroxy, oxo, halo, carboxy, unsubstituted ester, unsubstituted acyl, unsubstituted acyloxy, unsubstituted Ci-6 alkoxy, unsubstituted aryloxy, sulfonic acid, thiol, unsubstituted Ci-6 alkylthio, unsubstituted arylthio, sulfonyl, phosphoric acid, unsubstituted phosphate ester, unsubstituted phosphonic acid and unsubstituted phosphonate ester.
The term "18F" refers to an atom of the specific isotope of fluorine having 9 protons and 9 neutrons. The term "18F~" refers to an anion of the atom of the specific isotope of fluorine having 9 protons and 9 neutrons.
The term "protecting group", as used herein, takes its normal meaning in the art. Thus, a protecting group is a group which is introduced into a compound so that a subsequent step is chemo selective and does not affect the protected group. Protecting groups may be categorised as those suitable for protecting specific functional groups. Thus a protecting group may, for instance, be an alcohol protecting group, an amine protecting group or a carboxylic acid protecting group.
Process of the invention
The invention provides a process for producing an organic compound comprising an 18F atom, which process comprises treating a precursor organic compound comprising a -CY2X group with:
(i) [18F]fluoride; and
(ii) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein
X is a leaving group and
each Y is independently selected from F, CI, Br and H.
The [18F]fluoride and the activator do not usually come from the same compound (e.g. from a single salt). Components (i) and (ii) are typically added separately. The organic compound comprising an 18F atom is generally an organic compound wherein the X in the -CY2X group of the precursor organic compound has been replaced with 18F. The organic compound comprising an 18F atom or the precursor organic compound may be any suitable organic compound such as those discussed below. The precursor organic compound is typically a small organic compound, for instance having a molar mass of less than or equal to 1000 gmol"1, often less than or equal to 600 gmol"1.
X may be any suitable leaving group. Leaving groups are well known to the skilled person and include those groups which are susceptible to being replaced by another group, typically by nucleophilic substitution. X is typically a group selected from perfluoroalkylsulfonate groups (for instance triflate and nonaflate), sulfonate groups (for instance tosylate or mesylate), halide groups (for instance fluoride, chloride, bromide or iodide), carboxylate groups (for instance acetate or trifluoroacetate), nitrate groups and phosphate groups (for instance phosphate or alkylphosphate). Typically, X is a halide group. Preferably, the X is a leaving group which is CI, Br or I. Thus, X is often CI or Br. Each Y is typically independently selected from F and H. In particular, the -CY2X group is often -CF2X or -CFHX. In this embodiment, X is a leaving group which is usually a halide. Preferably, however, X in this embodiment is CI, Br or I, for instance CI or Br.
The precursor organic compound is often a compound of formula: R-CFXY; R-O-CFXY; R-N(R')-CFXY; R-S-CFXY; R-Se-CFXY; R-Te-CFXY; or a salt thereof, wherein: X is a leaving group, typically CI, Br or I; Y is F, CI, Br or H; R is a substituted or unsubstituted Ci- 60 organic group, typically a substituted or unsubstituted Ci-40 organic group; and R' is H or a substituted or unsubstituted Ci-40 organic group, which may optionally be bonded together with R to form a ring. For instance, the precursor compound may be a compound of formula R-O-CFXY; R-N(R')-CFXY; R-S-CFXY; R-Se-CFXY; R-Te-CFXY; or a salt thereof, wherein: X is a leaving group, typically CI, Br or I; Y is F, CI, Br or H; R is a substituted or unsubstituted Ci-40 organic group; and R' is H or a substituted or unsubstituted Ci-40 organic group, which may optionally be bonded together with R to form a ring.
Typically, the precursor organic compound is a compound of formula: R-CFXY; R-O- CFXY; R-S-CFXY; or a salt thereof, wherein: X is CI, Br or I; Y is F or H; and R is a substituted or unsubstituted Ci-40 organic group. In some cases, the precursor compound may be a compound of formula R-O-CFXY or a salt thereof. In other cases, the precursor compound may be a compound of formula R-S-CFXY or a salt thereof.
Often, X is CI and Y is F or H; or X is Br and Y is F. The -CFXY group is typically -CF2I, - CF2Br, -CF2CI, -CFHI, -CFHBr or -CFHC1. It may for instance be -CF2Br or -CFHC1. The process of the invention applies very generally to a wide range of compounds and R may therefore be a wide range of organic groups.
R may be any C1-60 organic group (which may be substituted or unsubstituted) and is typically a C1-60 organic group comprising one or more aryl or heteroaryl rings. R may be any Ci-40 organic group (which may be substituted or unsubstituted) and is typically a Ci-40 organic group comprising one or more aryl or heteroaryl rings. R may be a substituted or unsubstituted C3-40 organic group, a substituted or unsubstituted C5-35 organic group or a substituted or unsubstituted Cio-30 organic group. R typically comprises one to four aryl or heteroaryl groups. Substituted organic groups are themselves organic groups. Often, the Ci- 40 organic group is unsubstituted. R may alternatively be H in some cases. Often, R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. The aryl group or heteroaryl group is typically substituted as defined above. R may for instance be an aryl or heteroaryl group which is substituted with one or more aryl or heteroaryl groups, each of which may themselves be substituted or unsubstituted. As mentioned above, the identity of R is not particularly limited. Often, R is substituted or unsubstituted biphenyl.
R' may be any Ci-40 organic group (which may be substituted or unsubstituted) and is typically a Ci-40 organic group comprising one or more aryl or heteroaryl rings. R' may be a substituted or unsubstituted C3-40 organic group, a substituted or unsubstituted C5-35 organic group or a substituted or unsubstituted Cio-30 organic group. R' typically comprises one to four aryl or heteroaryl groups. Substituted organic groups are themselves organic groups. Often, the Ci-40 organic group is unsubstituted. R' may for instance be H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R' is typically H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl. R' is often unsubstituted Ci-6 alkyl or unsubstituted aryl. For instance, R' may be H, methyl, ethyl or phenyl.
The organic compounds comprising an 18F atom are often intended for use in medical imaging, for instance PET imagining. Thus, the organic compound comprising an 18F atom is often suitable for administration to a human subject and optionally suitable for use in PET imaging. In some embodiments, the invention provides a compound comprising an 18F atom for use in PET imaging, or a method of PET imaging comprising administering a compound comprising an 18F atom as defined herein to a patient.
The precursor organic compound may, for instance, be a precursor to a pharmaceutical compound wherein an F atom in the pharmaceutical compound has been replaced with X as defined herein, or a protected version thereof. Thus, the pharmaceutical compound comprises an F atom (which can be replaced by X). Lists of pharmaceutical compounds are readily available to the skilled person, for instance in the form of pharmacopoeias.
Specific examples of pharmaceutical compounds comprising an F atom are given below. Typically, the pharmaceutical compound is a selective serotonin reuptake inhibitor, a kinase inhibitor (e.g. a tyrosine kinase inhibitor), a prostaglandin, a substance P antagonist, a nonpeptidic protease inhibitor, a nonsteroidal anti-inflammatory drug, dipeptidyl peptidase-4 (DPP-4) inhibitor, a nucleoside analogue, a PDE4 inhibitor, an antibiotic drug, an
antihistamine drug, a potassium channel activator, a proton pump inhibitor or an anorectic drug. A protected version of the precursor compound is the precursor compound wherein one or more groups within the precursor compound have been protected. As the skilled person is well aware, it is often necessary to protect groups within a starting material (i.e. the precursor organic compound) before performing a reaction. Often, alcohol, amine and carboxylic acids in the precursor compound are protected using well known protecting groups. Examples of alcohol protecting groups include substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted -C(0)-C1-10 alkyl, substituted or unsubstituted -C1-10 alkylene-O- C1-10 alkyl optionally wherein the C1-10 alkylene group and C1-10 alkyl group may be bonded together to form a ring, and substituted or unsubstituted tri(C1-10 alkyl) silyl. Examples of carboxylic acid protecting group include substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted -C(0)-C1-10 alkyl, and substituted or unsubstituted tri(C1 -10 alkyl) silyl.
Examples of amine protecting group include substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted -C(0)-C1-10 alkyl, substituted or unsubstituted -C(0)-0-C1-10 alkyl, substituted or unsubstituted -S(0)2-aryl.
Often, a protecting group is selected from methyl, ethyl, tert-butyl, benzyl, carbobenzyloxy (Cbz), p-methoxybenzyl carbonyl (Moz), tert-butyloxycarbonyl (Boc), 9- fluorenylmethyloxycarbonyl (FMOC), acetyl and benzoyl. If the precursor organic compound is used as a protected version, the process of the invention often further comprises deprotecting the produced compound comprising an 18F atom.
Deprotection may be performed by any suitable method. Such methods are well known to the skilled person. Often, removing one or more protecting groups from (deprotecting) the compound comprising an 18F atom comprises performing hydrolysis on the compound. For instance, the process may further comprise treating the compound comprising an 18F atom with an aqueous acid, for instance aqueous HI, HBr or HC1.
The precursor organic compound often does not comprise a a carboxylic acid group or a hydroxyl group.
The process of the invention may be performed as a no-carrier added radiofluorination process. Thus, often substantially no 19F" is added during the reaction. For instance, no more than 1 mmol of 19F" is added during the reaction or no more than 1 μιηοΐ of 19F" is added during the reaction. Of course, some 19F" may already present during the reaction for instance from the precursor compound or by substitution of existing 19F atoms and "added" in this context means added from an external source. [18F]fluoride is commercially available or may be manufactured using a cyclotron or linear accelerator, for instance by bombardment of 180 with high energy protons. The [18F]fluoride is typically added in the form of a salt. The [18F]fluoride salt is typically a salt of
[18F]fluoride with an alkali metal cation or a quaternary ammonium cation, for instance Li18F, Na18F, K18F, Rb18F, [NMe4]18F, [NEt4]18F or [ Bu4]18F. Preferably, the salt also contains a complexing agent, for instance a crown ether or a cryptand. Typically, the fluoride is added as an alkali metal [18F]fluoride salt complexed with a cryptand. Examples of cryptands include aminopolyether 2.2.2 (K222), which is
commercially available as Kryptofix-222. Advantageously, the addition of such a cryptand enables the fluoride ion 18F" to be solubilized in a polar aprotic solvent, for instance acetonitrile or DMF. It also enables the formation of a 'naked fluoride ion' as a KF-K222 complex. In one embodiment, therefore, the source of 18F" is a K18F-K222 complex.
Alternatively, the source of 18F" may be [18F]TEAF (tetraethylammonium fluoride),
[18F]TBAF (tetrabutylammonium fluoride), [18F]CsF, or [18F]HF.
As discussed above, the organic compound comprising an 18F atom is often a pharmaceutical compound or a protected version thereof. The pharmaceutical compound may be as defined above, and the protecting groups may be as defined above. The pharmaceutical compound in its unradiolabelled state often comprises a group selected from -CF3, -CHF2, -O-CF3, -O- CHF2, -S-CF3 and -S-CHF2.
Pharmaceutical compounds comprising these groups may be readily identified by the skilled person, for instance by consulting a pharmacopeia. Preferably, the pharmaceutical compound (i.e. the compound from which the precursor organic compound, or the organic compound comprising the 18F atom, is derived) is celecoxib, riluzole, tiflorex, fenfluramine, fluoxetine, efavirenz, sorafenib, nilotinib, aprepitant, tripanavar, travoprost, dutasteride, sitagliptin, cinacalcet, nitisinone, trifluridine, zardaverine, riodipine, pantaprazole, garenoxacin, roflumilast, celikalim, flutiorex, toltrazuril, flomoxef sodium, or a pharmaceutically acceptable salt thereof.
The term "pharmaceutically acceptable salt" as used herein refers to a salt which is tolerated in a clinical setting. Examples of pharmaceutically acceptable salts includes salts derived by addition of an acid selected from acetic acid, adipic acid, benzenesulfonic acid, carbonic acid, citric acid, ethanesulfonic acid, formic acid, hydrobromic acid, hydrochloric acid, lactic acid, lauric acid, maleic acid, methanesulfonic acid, nitric acid, oxalic acid, phosphoric acid, salicylic acid, succinic acid, and sulfuric acid. References to "salt" in general include references to salts formed with any acid (for instance as defined herein) or with any anion (for instance as defined for the activator). When the compound comprising an 18F atom is a pharmaceutical or non-toxic compound, the process of the invention may further comprise using the compound in a method of PET imaging.
The activator comprises silver, gold, copper or platinum. Thus, the activator may comprise elemental silver, gold, copper or platinum, i.e. silver, gold, copper or platinum metal, or it may comprise a compound which comprises silver, gold, copper or platinum. If the activator comprises an elemental metal, it may be in the form of pellets, a mesh or a powder.
Preferably, the activator comprises a silver compound, a gold compound, a copper compound or a platinum compound. More preferably the activator comprises a silver compound or a gold compound. Most preferably, the activator is, or comprises, a silver compound.
If the activator comprises a silver, gold, copper or platinum compound, it may be a covalent compound, an organometallic compound or a salt. Typically, the compound is a salt. The compound is typically soluble in organic solvents. For instance, the compound may have a solubility of greater than or equal to 1 mmol/L in dichloromethane. The activator may therefore comprise a silver salt, a gold salt, a copper salt or a platinum salt. The metal may be in any oxidation state. The activator may for instance comprise a silver (I) salt, a silver (II) salt, a silver (III) salt, a gold (I) salt, a gold (III) salt, a copper (I) salt, a copper (II) salt, a platinum (II) salt or a platinum (IV) salt. Preferably, the activator comprises a silver (I) salt or a gold (I) salt. The activator salt typically comprises the metal as the cation and an anion. The anion is often the conjugate base of a strong acid. For instance, the anion may be selected from anions of formula (-OS(0)2Z)-, (-S(0)2Z)-, (-OC(O)Z)", triflate (OS02CF3) -, triflyl (S02CF3) " triflimide (N(S02CF3)2) ", oxide, fluoride, chloride, bromide, iodide, nitrate, perchl orate, carbonate, nonaflate (OS02(CF2)3CF3)", fluorosulfonate (OS02F)", tosylate (OS02-p- C6H4CH3)-, mesylate (OS02CH3)_, pivalate (OOCC(CH3)3)_, acetate, trifluoroacetate
(OOCCF3)" and tetrafluorob orate (BF4)" wherein Z is a group selected from halide, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C2-io alkenyl, substituted or unsubstituted C2-io alkynyl, perfluoroalkyl, substituted or unsubstituted C3-io cycloalkyl groups, substituted or unsubstituted aryl groups and substituted or unsubstituted heterocyclyl groups. Typically, the activator comprises:
a silver salt selected from silver triflate (AgOS02CF3), silver triflyl (AgS02CF3), silver triflimide (AgN(S02CF3)2), silver oxide (Ag20), silver fluoride (AgF), silver chloride (AgCl), silver bromide (AgBr), silver iodide (Agl), silver nitrate (AgN03), silver perchlorate (AgC104), silver carbonate (Ag2C03), silver nonaflate (AgOS02(CF2)3CF3), silver fluorosulfonate (AgOS02F), silver tosylate (AgOSC -p-CeFLtCFb), silver mesylate
(AgOS02CH3), silver pivalate (AgOOCC(CH3)3), silver acetate (AgOOCCH3), silver trifluoroacetate (AgOOCCF3), and silver tetrafluorob orate (AgBF4);
a gold salt selected from gold triflimide ((Ph3P)Au(N(S02CF3)2), triphenylphosphine gold triflimide ((Ph3P)Au(N(S02CF3)2), (2-di-tert-butylphosphinobiphenyl) gold triflimide (JohnPhosAu(N(S02CF3)2) triphenylphoshine gold chloride ((Ph3P)AuCl), triethylphosphine gold chloride ((Et3P)AuCl), l,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene gold chloride ((IPr)AuCl), methyl (triphenylphospine) gold ((Ph3P)AuMe); or
a copper salt selected from copper (I) triflate (CuOS02CF3), copper (II) triflate (Cu(OS02CF3)2), tetrakis(acetonitrile) copper(I) triflate (Cu(OS02CF3).4MeCN), and tetrakis(pyridine) copper(II) trilfate (Cu(OS02CF3)2.4Pyr).
Preferably, the activator comprises a silver (I) salt selected from silver (I) triflate
(AgOS02CF3), silver triflimide (AgN(S02CF3)2), silver (I) trifluoroacetate (AgOOCCF3) and silver (I) tetrafluorob orate (AgBF4). Most preferably, the salt is silver (I) triflate
(AgOS02CF3).
The activator typically consists of, or consists essentially of (e.g. greater than 95 wt%), said compound comprising silver, gold, copper or platinum or said elemental silver, gold, copper or platinum.
Typically, the amount of the activator is from 0.05 to 20 equivalents of the precursor organic compound. Often, similar amounts of activator and precursor organic compound are used during the process. For instance, the amount of the activator may be from 0.5 to 4 equivalents of the precursor organic compound. The molar ratio activator: precursor organic compound is preferably from 2: 1 to 1 :2. In some cases, the molar ratio is about 1 : 1.
The concentration of the precursor organic compound may be any suitable value, for instance from 0.01 M to 1 M. The concentration of the activator compound may be any suitable value, for instance from 0.01 M to 1 M. For instance, the concentration of the activator may be from 0.01 M to 0.6 M, preferably from 0.1 M to 0.4 M.
The use of the activator in the halogen exchange process of the invention allows
[18F]fluorination to occur at surprisingly low temperatures avoiding side reactions and maintaining high specificity. Typically, the process is carried out at a temperature of from 20°C to 100°C. Often, the temperature is greater than 30°C or greater than 40°C. Preferably, the process is carried out at a temperature of from 40°C to 90°C, more preferably from 50°C to 80°C. The temperature may, for instance, be from 55°C to 65°C.
The process of the invention is typically carried out for from 10 minutes to 2 hours, for instance for about 30 minutes.
The process of the invention is usually carried out in the presence of a solvent. Thus, the process often comprises treating a composition comprising a precursor organic compound comprising a -CY2X group and a solvent with:
(i) [18F] fluoride; and
(ii) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, wherein:
X is a leaving group; and
each Y is independently selected from F, CI, Br and H. The process of the invention may be carried out in the presence of any suitable solvent.
Examples of solvents include water, alcohol solvents (such as methanol, ethanol, n-propanol, isopropanol and n-butanol), ether solvents (such as dimethylether, diethylether and tetrahydrofuran), ester solvents (such as ethyl acetate), carboxylic acid solvents (such as formic acid and ethanoic acid), ketone solvents (such as acetone), amide solvents (such as dimethylformamide and diethylformamide), amine solvents (such as triethylamine), nitrile solvents (such as acetonitrile), sulfoxide solvents (dimethylsulfoxide), hydrocarbon solvents (such as hexane, cyclohexane and benzene) and halogenated solvents (such as
dichloromethane (DCM), dichloroethylene (DCE), chloroform, and chlorobenzene).
Typically, the solvent is a non-coordinating solvent, e.g. a solvent which does not comprise an -OH group. Thus, in some embodiments, the solvent may be any of those listed above except for water, an alcohol solvent or a carboxylic acid solvent. Typically, during the process of the invention a halogenated solvent is present.
Examples of halogenated solvents include benzotri chloride, bromoform, bromomethane, carbon tetrachloride, chlorobenzene, chlorofluorocarbon, chloroform, chlorom ethane, 1, 1- dichloro-l-fluoroethane, 1, 1-dichloroethane, 1,2-dichloroethane, 1, 1-dichloroethene, 1,2- dichloroethene, dichloromethane, diiodomethane, haloalkane, halomethane,
hexachlorobutadiene, hexafluoro-2-propanol, parachlorobenzotrifluoride, perfluoro-1,3- dimethylcyclohexane, perfluorodecalin, perfluorohexane, perfluoromethylcyclohexane, perfluoromethyldecalin, perfluorooctane, perfluorotripentylamine, tetrabromomethane, 1, 1,1,2-tetrachloroethane, 1, 1,2,2-tetrachloroethane, tetrachloroethylene, 1,3,5- trichlorobenzene, 1, 1, 1-trichloroethane, 1, 1,2-trichloroethane, trichloroethylene and 1,2,3- trichloropropane. Preferably the solvent is a halogenated solvent which is dichloromethane (DCM) or dichloroethylene (DCE), which may be 1, 1-dichloroethene, 1,2-dichloroethene or a mixture thereof.
The concentration of the [18F]fluoride is usually relatively low, as is typical during radiochemistry. For instance, the concentration of [18F]fluoride is typically less than 1 mM, less than 1 μΜ, or less than 1 nM. For instance, the concentration of [18F]fluoride may be from 1 pM to 1 mM, or lpM to 1 nM.
In a preferred embodiment of the invention, the activator comprises silver (I) triflate
(AgOSC CFs), dichloroethylene is present as a solvent, the reaction is carried out at a temperature of from 40°C to 80°C, and the amount of the silver (I) triflate is from 0.8 to 2 equivalents of the amount of precursor organic compound.
For instance, the process of the invention may comprise adding from 0.01 to 0.1 mmol of the precursor organic compound to a container comprising [18F]KF/K222 and from 0.01 to 0.1 mmol AgOTf in from 100 to 1000
Figure imgf000026_0001
DCM or DCE. The mixture is allowed to stir at a temperature from 40°C to 80°C for 10 to 1000 minutes, optionally after which time the reaction is quenched by the addition of EtOH/H2O.
In one embodiment of the invention, the process is conducted in an automated synthesizer. The automated synthesizer may be any suitable automated synthesizer, as are well known to the skilled person. Automated synthesizers may include one or more means for performing the process of the invention. For instance, an automated synthesizer may comprise one or more of (i) a means for mixing the reagents used in the process of the invention, (ii) a means for heating the mixed reagents of the invention and (iii) means for isolating the compound comprising an 18F atom. Such automated synthesizers may be used for the production of PET ligands comprising an 18F atom. Thus, the automated synthesizer may be suitable for use in a clinical setting, for instance in a imaging centre equipped with PET imaging and/or scanning apparatus.
An automated synthesizer may comprise one or more reagents used in the process of the invention. For example, the automated synthesizer may be pre-loaded with one or more reagents, for instance an activator as described herein or a precursor organic compound as described herein. Alternatively, the process of the invention may be conducted in an automated synthesizer, which process further comprises loading the automated synthesizer with one or more reagents. The reagents may be loaded into the automated synthesizer by inserting a pre-packaged amount of the reagent, for instance in the form of a capsule. For instance, the process of the invention may further comprise inserting a pre-packaged sample of an activator as defined herein or a precursor organic compound as defined herein into an automated synthesizer.
The process of the invention is useful for producing radiolabelled pharmaceutical compounds as described above. The invention also allows the production of precursors for useful reagents for performing -CF2 18F trifluoromethylation, and particularly Umemoto reagents (Zhang, Org. Biomol. Chem., 2014, 12, 6580-6589). Thus, in one embodiment the precursor organic compound is a compound of formula (1) or a salt thereof,
Figure imgf000027_0001
wherein:
Q is O, R', S, Se or Te, typically S, Se or Te;
X is CI, Br or I;
Y is F, CI, Br or H; each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more RA groups may be bonded together to form one or more rings;
R' is H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl; and each n is independently selected from 0, 1, 2, 3 and 4.
[18F]fluorinated compounds produced from compounds of formula (1) can easily be oxidised to produce trifluoromethylation agents such as Umemoto reagents. Thus, in one
embodiment, the process further comprises oxidising a compound of formula (1) or a salt thereof to produce a compound of formula (3) or a salt thereof:
Figure imgf000028_0001
wherein RA, n and Q are as defined for formula (1). Compounds of formula (3) herein are cationic and will be accompanied by an anion. The anion may be any suitable anion, for instance one of the anions in the silver (I) salts defined herein. Often the anion is
tetrafluorob orate or triflate.
Q is preferably S in formulae (1) and (3). Y is typically F or H in formulae (1) and (3). X and Y may be as further defined above.
Each n is typically 0, 1 or 2. Preferably each n is 0 or 1.
Typically, each RA is independently a group selected from unsubstituted C1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C2-10 alkynyl, unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl, wherein two or more RA groups may be bonded together to form one or more rings.
Often, both n are 0 and the compound of formula (1) is unsubstituted.
The organic precursor compound may be a compound of formula (la) or a salt thereof
Figure imgf000029_0001
wherein Q is O, S, Se or Te (usually S, Se or Te), preferably S, and X is CI, Br or I.
The invention also provides the use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom as defined herein. Thus, the invention provides the use of an activator as defined herein as an activator in [18F]fluorination of a precursor organic compound by halogen exchange.
The activator may be as defined above. Preferably, the activator comprises a silver (I) salt selected from silver (I) triflate (AgOS02CF3), silver triflimide (AgN(S02CF3)2), silver (I) trifluoroacetate (AgOOCCF3) and silver (I) tetrafluorob orate (AgBF4). More preferably, the activator comprises silver (I) triflate (AgOS02CF3).
The invention also provides a kit for [18F]radiolabelling an organic compound, which kit comprises:
(i) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum; and
(ii) a precursor organic compound comprising a -CY2X group, wherein X is a leaving group and each Y is independently selected from F, CI, Br and H.
The activator may be as further defined herein. The precursor organic compound may be as defined herein. The kit is typically in the form of packaging comprising components (i) and (ii), each of which may be present in one or more separate containers. Often, the kit further comprises instructions for carrying out a process as defined herein. The instructions may be written or may be in the form of an electronic data carrier.
The process of the invention allows facile radiolabelling of organic compounds such as those described above. This means that samples of radiolabelled compounds having high specific activity can be produced. The invention therefore provides a composition comprising a compound of formula:
R-CF2 18F;
R-CHF18F;
R-0-CF2 18F;
R-0-CHF18F;
R-N(R')-CF2 18F;
R-N(R')-CHF18F
R-S-CF2 18F;
R-S-CHF18F;
or a pharmaceutically acceptable salt thereof, and having a specific activity of greater than or equal to 50 GBq/μιηοΙ, wherein R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R and R' may be as further defined herein.
The specific activity of the composition is preferably greater than or equal to 70 GBq/μτηοΙ. In some cases, the specific activity of the composition is greater than or equal to 80
GBq/μιηοΙ or greater than or equal to 100 GBq/μτηοΙ.
Often, the compound in the composition has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
The process of the invention also allows access to [18F]radiolabelled compounds which have not been produced before. The invention therefore provides a compound, which compound has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
The invention also provides a compound of formula (2) or formula (3) or a salt of a compound of formula (2) or formula (3),
Figure imgf000036_0002
wherein:
Q is O, NR', S, Se or Te, preferably S, Se or Te;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di( C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more RA groups may be bonded together to form one or more rings;
R' is H, substituted or unsubstituted Ci-6 alkyl or substituted or unsubstituted aryl; and each n is independently selected from 0, 1, 2, 3 and 4.
As mentioned above, compounds of formula (3) are cationic and may have any suitable anion, for instance those defined for salt activators (e.g. tetrafluorob orate or triflate).
Q is preferably S. Each n is typically 0, 1 or 2. Preferably each n is 0 or 1. Typically, each RA is independently a group selected from unsubstituted C1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C2- 10 alkynyl, unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl, wherein two or more groups may be bonded together to form one or more rings.
Preferably, the compound of the invention is:
Figure imgf000037_0001
or a salt therof. For instance, the salt may comprise an anion as defined herein, for instance triflate or tetrafluorob orate.
Compounds of formula (3) may be referred to as Umemoto reagents and are useful as electrophilic sources of CF2 18F. These compounds can be reached by oxidising compounds of formula (2) to cause ring closure. The process may therefore further comprise producing and using compounds of formula (3).
Thus, the invention also provides a process for producing an organic compound comprising a -CF2 18F group, which process comprises:
(a) producing a compound of formula (2) or a salt thereof by a process as defined herein,
Figure imgf000037_0002
wherein:
Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more RA groups may be bonded together to form one or more rings; and
each n is independently selected from 0, 1, 2, 3 and 4; and
(b) oxidising the compound of formula (2) or a salt thereof to produce a compound of formula (3) or a salt thereof:
Figure imgf000038_0001
wherein:
Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more groups may be bonded together to form one or more rings; and each n is independently selected from 0, 1, 2, 3 and 4. The process may optionally further comprise: (c) trifluoromethylating a reactant organic compound by treating it with the compound of formula (3) or salt thereof.
Typically in compounds (2) and (3), each n is typically 0, 1 or 2. Preferably each n is 0 or 1. Typically in compounds (2) and (3), each RA is independently a group selected from unsubstituted C1-10 alkyl, unsubstituted C2-10 alkenyl, unsubstituted C2-10 alkynyl,
unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl, wherein two or more groups may be bonded together to form one or more rings. Preferably, the compound of formula
Figure imgf000039_0001
and the compound of formula (3) is
Figure imgf000039_0002
The reactant organic compound is typically a nucleophilic organic compound, i.e. a compound suitable for nucleophilic substitution of the cationic tricylic sulfur species. The reactant organic compound is oftent an organic compound comprising an alkyne group, an alkene group, a 1,3-diketone group, an aryl group, a boronic acid group or an amine group.
Step (b) of forming compound of formula (3) typically comprises treating the compound of formula (2) with a compound such as triflic anhydride (trifluoromethanesulfonic anhydride, 0(S02CF3)2). Step (c) of trifluoromethylating a reactant organic compound by treating it with the compound of formula (3), typically comprises mixing the reactant organic compound and the compound of formula (3) in a solvent and optionally heating the mixture.
The invention will now be described further by the following Examples. EXAMPLES
Production of precursor organic compounds
The following general procedures were used to produce the precursor organic compounds used in the radiolabelling procedures.
Ar-OCF2Br and Ar-OCHFCl - General procedure
Figure imgf000040_0001
To a solution of an appropriate carboxylic acid (1.0 mmol) in DCM (2 mL) was added DMF (7.7 0.1 eq.) and oxalyl chloride (129 μL., 1.5 mmol) at 0°C. The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. To the crude acyl chloride was added BrCC13 (3 mL), 4-dimethylaminopyridine (30.7 mg, 0.25 mmol) and sodium-N-hydroxy-2-thiopyridone (149 mg, 1.0 mmol). The reaction mixture was refluxed at 120°C for 2 hours and then concentrated in vacuo. The crude product was purified by silica gel column chromatography. Ar-CHFCl - General procedure
Figure imgf000041_0001
To a solution of an appropriate carboxylic acid (1.0 mmol) in DCM (2 mL) was added DMF (7.7 μL., 0.1 eq.) and oxalyl chloride (129 μL., 1.5 mmol) at 0°C. The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. To the crude acyl chloride was added degassed BrCC13 (3 mL), 4-dimethylaminopyridine (30.7 mg, 0.25 mmol) and sodium-N-hydroxy-2-thiopyridone (149 mg, 1.0 mmol). The reaction mixture was stirred under UV light irradiation for 12 hours. Tetrabutylammonium chloride (0.54g, 2.0 mmol) was added and stirring was continued for 2 hrs without irradiation. After concentrating in vacuo the crude product was purified by silica gel column chromatography.
Ar-CF2Br - General procedure 1
Figure imgf000041_0002
To a solution of an appropriate carboxylic acid (1.0 mmol) in DCM (2 mL) was added DMF (7.7 μL, 0.1 eq.) and oxalyl chloride (129 μL, 1.5 mmol) at 0°C. The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. To the crude acyl chloride was added degassed BrCC13 (3 mL), 4-dimethylaminopyridine (30.7 mg, 0.25 mmol) and sodium-N-hydroxy-2-thiopyridone (149 mg, 1.0 mmol). The reaction mixture was stirred under irradiation from a sunlamp (300W) for 12 hours and concentrated in vacuo. The crude product was purified by silica gel column chromatography. Ar-CF2Br - General procedure 2
Figure imgf000042_0001
To a solution of an appropriate difluoromethylarene (10.0 mmol) in degassed CC14 (30 mL) was added N-bromosuccinimide (NBS, 3.02g, 17 mmol). The reaction mixture was stirred under irradiation from a sunlamp (300W) for 18 hours, after which it was filtered over
Celite®, washed with saturated NaS203 solution (30 mL), H2O (30 mL), then dried (Na2S04) and concentrated in vacuo. The crude product was purified by silica gel column
chromatography.
Ar-SCF2Br - General procedure 1
Figure imgf000042_0002
A suspension of sodium hydride (60% on oil ; 0.30g, 7.5 mmol) in degassed NMP (5 mL) was cooled in an ice bath and the appropriate thiophenol (5 mmol) was added in one portion. The mixture was stirred for 10 min at 0°C followed by 30 min at room temperature. The reaction mixture was then cooled to -78°C in a dry-ice acetone cooling bath and
dibromodifluoromethane (0.55 mL, 6 mmol) was added in one portion. The reaction flask was sealed, the cooling bath removed and the reaction mixture was stirred overnight (18 hrs) at room temperature after which it was carefully quenched by addition of H2O (30 mL). The crude mixture was extracted with MTBE (3 x 25 mL) and the organic layers were washed with H2O (30 mL), brine (30 mL), dried over Na2SC"4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography.
Ar-SCF2Br - General Procedure 2
Figure imgf000042_0003
A solution of sodium dithionite (85% pure; 1.54g, 7.5 mmol) and disodium
hydrogenphosphate (1.06g, 7.5 mmol) in H2O (20 ml) was added in one portion to a mixture of the appropriate arenedisulfide in a mixture of DMF (75 mL) and H2O (5 mL) under cooling from a water bath. Dibromodifluoromethane (1.37 mL, 15 mmol) was added in one portion after which the reaction mixture was stirred overnight (18 hrs) at room temperature. The mixture was poured into H2O (200 mL) and extracted with MTBE (3 x 100 mL). The organic extracts were washed with H2O (100 mL), brine (100 mL), dried over Na2SC"4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography.
General radiochemical procedure
The following general radiochemical procedures were used to produce [18F]radiolabelled compounds. Procedures using activators other than AgOTf were performed by replacing the AgOTf with the other activator in an amount of 0.04 mmol (unless otherwise stated).
Ar-CF2Br to Ar-CF2-18F
Figure imgf000043_0001
To a V-vial containing [18F]KF/K222 and AgOTf (0.04 mmol) is added substrate (0.04 mmol) in DCM (300 μL). This mixture is allowed to stir at rt for 20 minutes, after which time the reaction is quenched by the addition of EtOH/H2O (9: 1, 500 μL).
Ar-SCF2Br to Ar-SCF2-18F
Figure imgf000043_0002
To a V-vial containing [18F]KF/K222 and AgOTf (0.04 mmol) is added substrate (0.04 mmol) in DCM (300 μL). This mixture is allowed to stir at rt for 20 minutes, after which time the reaction is quenched by the addition of EtOH/H2O (9: 1, 500 μL). Ar-OCF2Br to Ar-OCF2-18F
Figure imgf000044_0001
To a V-vial containing [18F]KF/K222 and AgOTf (0.08 mmol) is added substrate (0.04 mmol) in DCE (300 This mixture is allowed to stir at 60 °C for 20 minutes, after which time the reaction is quenched the addition of ΕΐΟΗ/Η20 (9: 1, 500 μL).
Ar-OCHFCl to Ar-OCHF-18F
Figure imgf000044_0002
To a V-vial containing [18F]KF/K222 and AgOTf (0.04 mmol) is added substrate (0.04 mmol) in DCM (300 μL). This mixture is allowed to stir at rt for 20 minutes, after which time the reaction is quenched by the addition of EtOH/FbO (9: 1, 500 μL).
For Ar-CF2Br to Ar-CF2-18F and Ar-SCF2Br to Ar-SCF2-18F, yields can be increased by the use of the following conditions: to a V-vial containing [18F]KF/K222 and AgOTf (0.08 mmol) is added substrate (0.04 mmol) in DCE (300 μL). This mixture is allowed to stir at 60 °C for 20 minutes, after which time the reaction is quenched the addition of EtOH/FbO (9: 1, 500 μL).
Optimisation and substrate scope
Throughout the examples, percentages given for products represent radiochemical yield (RCY).
Aryl-CF2-Br to Aryl-CFr-18F
The process conditions for this conversion were optimised by performing the procedures below. A solvent screen was performed confirming that non-coordinating solvents such as dichloromethane (DCM) and dichloroethylene (DCE) are preferred.
Figure imgf000045_0001
(0.04 mrnol)
Figure imgf000045_0004
The reaction was performed with and without the silver triflate confirming the importance of the activator in the halogen exchange radiofluorination.
Figure imgf000045_0002
The effect of the presence of aryl halides was investigated.
Figure imgf000045_0003
Figure imgf000045_0005
The metal catalysts were screened showing that a wide range of activators can be used.
Figure imgf000046_0001
Figure imgf000046_0003
The effect of the stoichiometry was investigated.
Figure imgf000046_0002
Figure imgf000046_0004
The "thermal reaction" without the halogen exchange activating activator was performed as a comparison.
Figure imgf000047_0001
Figure imgf000047_0003
The reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor aryl compounds was found to be possible.
Figure imgf000047_0002
Figure imgf000048_0003
The activators were screened.
Figure imgf000048_0001
Figure imgf000048_0004
The activator, solvent and temperature were screened.
Figure imgf000048_0002
Figure imgf000048_0005
The reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluonnation of electron rich and electron poor substrates was found to be possible.
Figure imgf000049_0001
Figure imgf000049_0003
A comparison was made between the method of the invention and a thermal method. The method of the invention produces substantially higher radiochemical yields (RCY).
Metai Catalysed
Figure imgf000049_0002
Thermal Reaction
Figure imgf000050_0001
The reaction was then performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor substrates was found to be possible.
Figure imgf000050_0002
Figure imgf000050_0003
A solvent screen was performed which demonstrated that non-coordinating solvents such as DCM and DCE are preferred.
Figure imgf000051_0001
Figure imgf000051_0003
A screen of metal activators was performed.
Figure imgf000051_0002
Figure imgf000051_0004
The thermal reaction was performed in a number of solvents for comparison.
Figure imgf000052_0001
Figure imgf000052_0002
Different stoichiometnes of the activator and substrate precursor compound were investigated.
Figure imgf000053_0001
Figure imgf000053_0003
The reaction was performed on a number of different substrates to determine the substrate scope of the reaction. Radiofluorination of electron rich and electron poor substrates was found to be possible.
Figure imgf000053_0002
Figure imgf000054_0001
Production of radiolabelled celecoxib
The COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) celecoxib was successfully [18F]radiolabelled using the process of the invention at 60°C. A protected precursor comprising a -CF2Br group was prepared and this was converted by the process of the invention at two different temperatures.
Figure imgf000055_0001
Figure imgf000055_0002

Claims

1. A process for producing an organic compound comprising an 18F atom, which process comprises treating a precursor organic compound comprising a -CY2X group with:
(i) [18F] fluoride; and
(ii) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum wherein:
X is a leaving group; and
each Y is independently selected from F, CI, Br and H.
2. A process according to claim 1, wherein the precursor organic compound is a compound of formula:
R-CFXY;
R-O-CFXY;
R-N(R')-CFXY
R-S-CFXY;
R-Se-CFXY;
R-Te-CFXY; or
a salt thereof,
wherein:
X is CI, Br or I;
Y is F CI, Br or H;
R is a substituted or unsubstituted Ci-40 organic group; and
R' is H or a substituted or unsubstituted Ci-40 organic group, which may optionally be bonded together with R to form a ring.
3. A process according to claim 1 or claim 2, wherein the precursor organic compound is a compound of formula:
R-CFXY;
R-O-CFXY;
R-S-CFXY; or
a salt thereof,
wherein: X is CI, Br or I;
Y is F or H; and
R is a substituted or unsubstituted Ci-40 organic group. 4. A process according to claim 2 or claim 3, wherein:
R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
5. A process according to any one of claims 2 to 4, wherein:
X is CI and Y is F or H; or
X is Br and Y is F.
6. A process according to any one of the preceding claims, wherein the precursor organic compound is a precursor to a pharmaceutical compound wherein an F atom in the pharmaceutical compound has been replaced with X as defined in claim 1, or a protected version thereof.
7. A process according to any one of the preceding claims, wherein substantially no 19F" is added during the reaction. 8. A process according to any one of the preceding claims, wherein the fluoride is added in the form of a salt.
9. A process according to any one of the preceding claims, wherein the fluoride is added as an alkali metal [18F]fluoride salt complexed with a cryptand.
10. A process according to any one of the preceding claims, wherein the organic compound comprising an 18F atom is a pharmaceutical compound or a protected version thereof. 11. A process according to claim 6 or claim 10, wherein the pharmaceutical compound is celecoxib, riluzole, tiflorex, fenfluramine, fluoxetine, efavirenz, sorafenib, nilotinib, aprepitant, tripanavar, travoprost, dutasteride, sitagliptin, cinacalcet, nitisinone, trifluridine, zardaverine, riodipine, pantaprazole, garenoxacin, roflumilast, celikalim, flutiorex, toltrazuril, flomoxef sodium or a pharmaceutically acceptable salt thereof.
12. A process according to any one of the preceding claims wherein the activator comprises a silver compound, a gold compound, a copper compound or a platinum compound, preferably a silver compound or a gold compound.
13. A process according to any one of the preceding claims, wherein the activator comprises:
a silver salt selected from silver triflate (AgOS02CF3), silver triflyl (AgS02CF3), silver triflimide (AgN(S02CF3)2), silver oxide (Ag20), silver fluoride (AgF), silver chloride (AgCl), silver bromide (AgBr), silver iodide (Agl), silver nitrate (AgN03), silver perchlorate (AgC104), silver carbonate (Ag2C03), silver nonaflate (AgOS02(CF2)3CF3), silver fluorosulfonate (AgOS02F), silver tosylate (AgOSCh-p-CeFLtCFfc), silver mesylate
(AgOS02CH3), silver pivalate (AgOOCC(CH3)3), silver acetate (AgOOCCFfc), silver trifluoroacetate (AgOOCCF3), and silver tetrafluorob orate (AgBF4);
a gold salt selected from gold triflimide ((Ph3P)Au(N(S02CF3)2), triphenylphosphine gold triflimide ((Ph3P)Au(N(S02CF3)2), (2-di-tert-butylphosphinobiphenyl) gold triflimide (JohnPhosAu(N(S02CF3)2) triphenylphoshine gold chloride ((Ph3P)AuCl), triethylphosphine gold chloride ((Et3P)AuCl), l,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene gold chloride ((IPr)AuCl), methyl (triphenylphospine) gold ((Ph3P)AuMe); or
a copper salt selected from copper (I) triflate (CuOS02CF3), copper (II) triflate
(Cu(OS02CF3)2), tetrakis(acetonitrile) copper(I) triflate (Cu(OS02CF3).4MeCN), and tetrakis(pyridine) copper(II) trilfate (Cu(OS02CF3)2.4Pyr).
14. A process according to any one of the preceding claims, wherein the activator comprises a silver (I) salt selected from silver (I) triflate (AgOS02CF3), silver triflimide
(AgN(S02CF3)2), silver (I) trifluoroacetate (AgOOCCF3) and silver (I) tetrafluorob orate (AgBF4), preferably wherein the salt is silver (I) triflate (AgOS02CF3).
15. A process according to any one of the preceding claims, wherein the amount of the activator is from 0.5 to 4 equivalents of the precursor organic compound.
16. A process according to any one of the preceding claims, comprising carrying out the process at a temperature of from 20°C to 100°C, preferably from 40°C to 90°C, more preferably from 50°C to 80°C.
17. A process according to any one of the preceding claims, comprising carrying out the process for a time of from 10 minutes to 2 hours. 18. A process according to any one of the preceding claims, wherein a halogenated solvent is present, preferably wherein the halogenated solvent is dichloromethane (DCM) or dichloroethylene (DCE).
19. A process according to any one of the preceding claims, wherein the concentration of [18F]fluoride is from 1 pM to 1 mM.
20. A process according to any one of the preceding claims, wherein the activator comprises silver (I) triflate (AgOSChCFs), dichloroethylene is present as a solvent, the reaction is carried out at a temperature of from 40°C to 80°C, and the amount of the silver (I) triflate is from 0.8 to 2 equivalents of the amount of precursor organic compound.
21. A process according to any one of the preceding claims, wherein the process is carried out in an automated synthesizer.
22. A process according to any one of the preceding claims wherein the precursor compound is a compound of formula (1) or a salt thereof,
Figure imgf000059_0001
wherein:
Q is O, NR', S, Se or Te, preferably S, Se or Te, more preferably S;
X is CI, Br or I;
Y is F CI, Br or H; each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more RA groups may be bonded together to form one or more rings;
R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
each n is independently selected from 0, 1, 2, 3 and 4.
23. Use of an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum, in a process for producing an organic compound comprising an F atom as defined in any one of claims 1 to 22.
24. Use according to claim 23, wherein the activator comprises a silver (I) salt selected from silver (I) triflate (AgOS02CF3), silver triflimide (AgN(S02CF3)2), silver (I)
trifluoroacetate (AgOOCCF3) and silver (I) tetrafluorob orate (AgBF4), preferably wherein the silver (I) salt is silver (I) triflate (AgOS02CF3).
25. A kit for [18F]radiolabelling an organic compound, which kit comprises:
(i) an activator which comprises a compound comprising silver, gold, copper or platinum, or which comprises elemental silver, gold, copper or platinum; and (ii) a precursor organic compound comprising a -CY2X group, wherein X is a leaving group and each Y is independently selected from F, CI, Br and H. 26. A kit according to claim 25, wherein the activator is as further defined in any one of claims 12 to 14, and wherein the precursor organic compound is as defined in any one of claims 2 to 6 and 22.
27. A kit according to claim 25 or claim 26, which further comprises instructions for carrying out a process as defined in any one of claims 1 to 22.
A composition comprising a compound of formula
R-CF2 18F;
R-CHF18F;
R-0-CF2 18F;
R-0-CHF18F;
R-N(R')-CF2 18F;
R-N(R')-CHF18F
R-S-CF2 18F;
R-S-CHF18F: or
a pharmaceutically acceptable salt thereof,
and having a specific activity of greater than or equal to 50 GBq/μιηοΙ,
wherein:
R is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; and R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
29. A composition according to claim 28, wherein the compound has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
30. A compound, which compound has any one of the following formulae or is a pharmaceutically acceptable salt of a compound of any one of the following formulae:
Figure imgf000065_0002
Figure imgf000066_0001
Figure imgf000067_0001
31. A compound of formula (2), formula (3) or a salt thereof
Figure imgf000067_0002
wherein:
Q is O, NR', S, Se or Te, preferably S, Se or Te, more preferably S;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more RA groups may be bonded together to form one or more rings;
R' is H, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
each n is independently selected from 0, 1, 2, 3 and 4.
32. A compound according to claim 31, which compound is:
Figure imgf000068_0001
33. A process for producing an organic compound comprising a -CF2 18F group, which process comprises:
(a) producing a compound of formula (2) or a salt thereof by a process as defined in any one of claims 1 to 5, 7 to 9 and 12 to 22,
Figure imgf000069_0001
wherein:
Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more groups may be bonded together to form one or more rings; and
each n is independently selected from 0, 1, 2, 3 and 4;
(b) oxidising the compound of formula (2) or a salt thereof to produce a compound of formula (3) or a salt thereof:
Figure imgf000069_0002
wherein:
Q is O, S, Se or Te, preferably S, Se or Te, more preferably S;
each RA is independently a group selected from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C3-20 cycloalkyl, substituted or unsubstituted heterocyclyl,
substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cyano, amino, C1-10 alkylamino, di(C1-10)alkylamino, arylamino, diarylamino, arylalkylamino, amido, acylamido, hydroxy, halo, carboxy, ester, acyl, acyloxy, C1-20 alkoxy, aryloxy, haloalkyl, sulfonic acid, thiol, C1-10 alkylthio, arylthio, sulfonyl, phosphoric acid, phosphate ester, phosphonic acid and phosphonate ester, wherein two or more groups may be bonded together to form one or more rings; and
each n is independently selected from 0, 1, 2, 3 and 4; and optionally (c) trifluoromethylating a reactant organic compound by treating it with the compound of formula (3).
34. A process according to claim 33, wherein the compound of formula (2) is
Figure imgf000070_0001
and the compound of formula (3) is
Figure imgf000070_0002
35. A process according to claim 33 or claim 34 wherein the reactant organic compound is a nucleophilic organic compound, optionally an organic compound comprising an alkyne group, an alkene group, a 1,3-diketone group, an aryl group, a boronic acid group or an amine group.
PCT/GB2016/050758 2015-03-20 2016-03-18 Fluorination process WO2016151295A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504755.8A GB201504755D0 (en) 2015-03-20 2015-03-20 Fluorination process
GB1504755.8 2015-03-20

Publications (1)

Publication Number Publication Date
WO2016151295A1 true WO2016151295A1 (en) 2016-09-29

Family

ID=53052145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/050758 WO2016151295A1 (en) 2015-03-20 2016-03-18 Fluorination process

Country Status (2)

Country Link
GB (1) GB201504755D0 (en)
WO (1) WO2016151295A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2560750A (en) * 2017-03-24 2018-09-26 Taher Darreh Shori Biological methods
CN109053660A (en) * 2018-07-13 2018-12-21 青岛农业大学 Coumarin kind compound containing trifluoromethylthio, its synthetic method and its application
CN109704915A (en) * 2018-12-24 2019-05-03 西安彩晶光电科技股份有限公司 A kind of polyhalo biphenyl compound and preparation method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080561A1 (en) * 2007-12-20 2009-07-02 General Electric Company Selective radiolabeling of biomolecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080561A1 (en) * 2007-12-20 2009-07-02 General Electric Company Selective radiolabeling of biomolecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DION VAN DER BORN ET AL: "A Universal Procedure for the [ 18 F]Trifluoromethylation of Aryl Iodides and Aryl Boronic Acids with Highly Improved Specific Activity", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 41, 26 August 2014 (2014-08-26), DE, pages 11046 - 11050, XP055270627, ISSN: 1433-7851, DOI: 10.1002/anie.201406221 *
L. CARROLL ET AL: "Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [ 18 F]CF 3 -containing PET probes", CHEMICAL COMMUNICATIONS - CHEMCOM, vol. 51, no. 40, 1 January 2015 (2015-01-01), GB, pages 8439 - 8441, XP055270624, ISSN: 1359-7345, DOI: 10.1039/C4CC05762G *
MICKAEL HUIBAN ET AL: "A broadly applicable [18F]trifluoromethylation of aryl and heteroaryl iodides for PET imaging", NATURE CHEMISTRY, vol. 5, no. 11, 8 September 2013 (2013-09-08), GB, pages 941 - 944, XP055270319, ISSN: 1755-4330, DOI: 10.1038/nchem.1756 *
T. RÜHL ET AL: ")-mediated 18 F-trifluoromethylation of arenes: Rapid synthesis of 18 F-labeled trifluoromethyl arenes", CHEMICAL COMMUNICATIONS - CHEMCOM, vol. 50, no. 45, 1 January 2014 (2014-01-01), GB, pages 6056 - 6059, XP055270311, ISSN: 1359-7345, DOI: 10.1039/C4CC01641F *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2560750A (en) * 2017-03-24 2018-09-26 Taher Darreh Shori Biological methods
WO2018172557A1 (en) * 2017-03-24 2018-09-27 Darreh Shori Taher Biological methods
CN109053660A (en) * 2018-07-13 2018-12-21 青岛农业大学 Coumarin kind compound containing trifluoromethylthio, its synthetic method and its application
CN109053660B (en) * 2018-07-13 2022-04-26 青岛农业大学 Compound containing trifluoromethylthio coumarin, and synthetic method and application thereof
CN109704915A (en) * 2018-12-24 2019-05-03 西安彩晶光电科技股份有限公司 A kind of polyhalo biphenyl compound and preparation method

Also Published As

Publication number Publication date
GB201504755D0 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
EP3119737B1 (en) Fluorination method
JP2007532524A (en) Fluorination method
WO2016151295A1 (en) Fluorination process
Verhoog et al. Ring opening of epoxides with [18 F] FeF species to produce [18 F] fluorohydrin PET imaging agents
JP5715823B2 (en) Method for producing marked purine derivatives, the purine derivatives, and uses thereof
KR102063498B1 (en) Process for producing fluorinated compounds using alcohol solvent having unsaturated hydrocarbon
US11779665B2 (en) Electrochemical flash fluorination and radiofluorination
JP2013542187A (en) New radioactive tracer
WO2010133851A1 (en) Preparation of labelled compounds
JP2013537239A (en) New precursor
JP6035328B2 (en) Method for producing fluorine 18-labeled flumazenil using diaryliodonium salt precursor
EP3849956A1 (en) Fluorination method
WO2023047104A1 (en) Difluorocarbene radiosynthesis
TWI556832B (en) Method for production of f-18 labeled aβ ligand
KR101592291B1 (en) Method for preparing [18F]Fluoro-L-Dopa with high radiochemical and enantiomeric purity
EP2590910A2 (en) Fluorine radiolabelling process
CA2830774A1 (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
JP2013538234A (en) Isotope carbon choline analogue
US20090226368A1 (en) Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16713018

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16713018

Country of ref document: EP

Kind code of ref document: A1